

DOCUMENTS
2026 ANNUAL GENERAL MEETING
OF SHAREHOLDERS
IMEXPHARM CORPORATION

March 2026



TABLE OF CONTENTS



CONTENTS	
1	Agenda of the 2026 Annual General Meeting of Shareholders
2	Meeting Regulations of the 2026 AGM
Reports	
1	Report and Assessment on the activities of the Board of Directors In 2025 Orientation Plan For 2026
2	Report on Business and Financial Performance In 2025 - Operational Plan of the Executive Board for 2026
3	Report of the Audit Committee and the Independent Member of the Board of Directors - Mr. Hoang Duc Hung
4	Report on Performance Assessment of Independent Member of the Board of Directors - Mr. Chung Suyong
5	Report on 2025 remuneration and operating expenses of the Board of Directors and the Board Committees
Proposals	
1	Proposal on the audited 2025 Financial Statements
2	Auditor's opinion
3	Profit distribution for 2025- Dividend plan for 2026
4	Proposal on the 2026 Business Target and Plan
5	Proposal on Operating Expenses of the Board of Directors and the Board Committees for 2026
6	Proposal on Selection of an independent auditor for 2026
7	Proposal on amendment and supplementation of business lines of Imexpharm Corporation
8	Proposal on amendments and supplements to the Company's Charter
Resolution	
1	Voting Slip
2	Draft Resolution for the 2026 Annual General Meeting of Shareholders



**MEETING REGULATIONS ON
ANNUAL GENERAL MEETING OF SHAREHOLDERS IN 2026
IMEXPHARM CORPORATION**

Pursuant to:

- *Law on Enterprises No. 59/2020/QH14 dated 17 June, 2020 and its subsequent amendments and supplements;*
- *Law on Securities No. 54/2019/QH14 dated November 26, 2019, and its subsequent amendments and supplements;*
- *Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government regulating the detailed implementation of a number of articles of the Law on Securities;*
- *Decree No. 245/2025/ND-CP dated September 11, 2025 of the Government amending and supplementing several articles of Decree No. 155/2020/ND-CP;*
- *Charter on organization and operation of Imexpharm Corporation;*
- *Internal regulations on corporate governance of Imexpharm Corporation.*


To ensure the success of the 2026 Annual General Meeting of Shareholders of Imexpharm Corporation, the Board of Directors has formulated these Regulations on the principles of conduct, proceedings, and voting at the Meeting for the Annual General Meeting of Shareholders as follows:

1. PURPOSE

- To ensure that the proceedings, conduct principles, and voting procedures at the Annual General Meeting of Shareholders of Imexpharm Corporation are conducted in accordance with regulations and achieve a successful outcome.
- The Resolutions of the Annual General Meeting of Shareholders represent the collective will of the General Meeting, fulfilling the aspirations and interests of shareholders in full compliance with the law.

2. APPLICABILITY AND SCOPE

- Subject entities: All shareholders, authorized representatives of shareholders holding shares of Imexpharm Corporation, and invited guests attending the Annual General Meeting of Shareholders of Imexpharm Corporation shall strictly abide by and comply with the provisions of these Regulations, the Company's Charter, and current legal regulations;





- Scope of application: These Regulations shall apply to the organization and conduct of the 2026 Annual General Meeting of Shareholders of Imexpharm Corporation.

3. INTERPRETATION OF TERMS/ ABBREVIATIONS

- Company : Imexpharm Corporation;
- BODs : Board of Directors;
- OC : Organizing Committee;
- AGM/General Meeting/Meeting : Annual General Meeting of Shareholders;
- Delegates : Shareholders and Representatives (Authorized Representatives);
- Electronic Voting : is the act of Delegates using internet-connected devices to cast their votes through an electronic voting system as prescribed by the Company and notified to the delegates at the time of meeting registration
- Electronic Voting System : is a system to be used and provided by the Company to furnish Delegates with tools to exercise their related rights when attending the Annual General Meeting of Shareholders

4. CONTENTS OF THE REGULATION

4.1 Conditions for Conducting the General Meeting of Shareholders

- The AGM shall be conducted if the number of attending Delegates represents more than 50% of the total voting shares;
- If the required quorum is not met, the convener shall cancel the Meeting. The AGM must be re-convened within 30 (thirty) days from the scheduled date of the first meeting. The second convocation of the AGM shall proceed only if the attending shareholders represent at least 33% of the total voting shares;
- If the second convocation cannot be conducted due to the lack of a required quorum, the third convocation of the AGM may be convened within 20 (twenty) days from the scheduled date of the second meeting. In this case, the AGM shall proceed



regardless of the total voting shares represented by the attending shareholders, shall be deemed valid, and shall have the power to decide on all matters intended to be approved at the first AGM.

- Note: The proportion of shareholders attending the AGM shall be determined to include:
 - Delegates physically present at the meeting venue who have completed registration with the Organizing Committee;
 - Shareholders who vote remotely prior to the opening of the AGM by submitting valid voting forms to the Company within the prescribed deadline and in the prescribed manner. Valid voting forms received before the opening of the AGM will be consolidated by the Organizing Committee and counted towards the total number of shareholders attending and voting at the AGM.

4.2 Conditions for Shareholder Participation in the Meeting


Shareholders with voting rights of the Company, as named in the List of Shareholders as of the Record Date (March 17, 2026), are entitled to attend the AGM. They may attend in person or authorize one or several other individuals or organizations to attend on their behalf, or participate through the format prescribed in Clause 3, Article 144 of the Law on Enterprises and Article 16 of the Company's Charter. In cases where more than one authorized representative is appointed in accordance with the law, the specific number of shares for each representative must be determined.

4.3 Guests at the Meeting

- As Company management positions, invited guests, and members of the Organizing Committee who are not shareholders of the Company but are invited to attend the AGM.
- Guests shall not participate in discussions or provide comments at the Meeting, *(except when invited by the Chairperson, or having pre-registered with the Organizing Committee and obtained the Chairperson's approval)*

4.4 Delegates attending the AGM shall comply with the following regulations:

- Be punctual, dress in formal and polite attire, undergo security checks (if any), present personal identification, and comply with other requirements as requested by the Meeting's Organizing Committee.
- Receive meeting documents and relevant materials at the Reception Desk located in front of the General Meeting Hall;




3844
3 TY
C PH
PHA
ÔNG

- Delegates arriving after the Meeting has been officially opened are entitled to register immediately and subsequently participate and vote at the Meeting upon completion of their registration. The Chairperson is not obligated to suspend the Meeting for latecomers to register, and the validity of any matters already voted upon prior to their arrival shall remain unchanged;
- Please set mobile phones to silent or vibrate mode. Should a call be necessary, please step outside the Meeting Hall to converse;
- No smoking is permitted and order must be maintained within the Meeting Hall;
- Comply with the regulations issued by the Organizing Committee and the directions of the Chairperson presiding over the Meeting;
- In the event that any Delegate or Guest fails to comply with the aforementioned inspection procedures, measures, or regulations, the Chairperson, after careful consideration, may refuse entry to or expel such person from the Meeting venue to ensure the Meeting proceeds in an orderly manner and in accordance with the pre-approved agenda.

4.5 Chairperson and Presidium:

- The Presidium consists of 01 (one) Chairperson and other Members designated by the Chairperson.
- The Chairman of the Board of Directors shall serve as Chairperson, or may authorize another BOD member to chair the AGM convened by the Board of Directors. If the Chairman is absent or temporarily incapacitated, the remaining BOD members shall elect one among themselves as Chairperson by majority vote. If no Chairperson can be elected in this manner, the Chairman of the Audit Committee shall facilitate the AGM in electing a Chairperson, and the candidate receiving the highest number of votes shall assume the role.
- The Chairperson may undertake necessary actions to conduct the AGM in a valid and orderly manner, in accordance with the approved agenda, and to reflect the aspirations of the majority of attending delegates:
 - Seating arrangements at the AGM venue;
 - Ensure the safety and security of all persons present at the Meeting venues
- Facilitate the attendance (or continued attendance) of shareholders at the Meeting. The Convener of the AGM shall have full discretion to modify the aforementioned measures and implement all necessary actions. Such measures may include issuing entry permits or adopting other alternative forms.


33-C.1
CP
AM
RM
THAP



- The Chairperson of the AGM shall have the following powers:
 - Require all attendees to undergo security inspections or other lawful and reasonable security measures;
 - Request competent authorities to maintain meeting order; expel from the AGM any persons who fail to comply with the Chairperson's presiding authority, intentionally cause public disorder, obstruct the normal progress of the Meeting, or disregard security inspection requirements
- The Chairperson has the power to adjourn a AGM for which a sufficient number of delegates have registered for attendance, for a maximum period of 03 (three) working days from the scheduled opening date, and may only adjourn the Meeting or change the meeting venue in the following cases:
 - The meeting venue does not have sufficient suitable seating for all attendees;
 - Communication facilities at the meeting venue fail to ensure that attending shareholders can participate, discuss, and vote;
 - There are attendees who obstruct or disrupt meeting order, posing a risk that the Meeting cannot be conducted fairly and lawfully.
- Duties and Responsibilities of the Presidium:
 - Preside over and manage the AGM's proceedings in accordance with the tentative agenda proposed by the Board of Directors and subsequently approved by the AGM;
 - Guide the Delegates and the Meeting in discussing the items included in the agenda;
 - Submit draft resolutions and conclude on necessary matters for the General Meeting's voting;
 - Address and respond to matters raised by the General Meeting;
 - Resolve matters arising throughout the course of the General Meeting.
- Working Principles of the Presidium: The Presidium shall operate on the principles of collective leadership and democratic centralism, with decisions made by majority vote.

4.6 Meeting Secretaries

- The Chairperson shall appoint one or several persons to serve as Meeting Secretaries;



- Duties and Responsibilities of the Meeting Secretariat:
 - Provide full and truthful records of the Meeting's proceedings;
 - Receive and synthesize questions raised by the Delegates;
 - Prepare the Meeting Minutes and draft the AGM's Resolutions;
 - Assist the Chairperson in disclosing information regarding the AGM and notifying Shareholders in compliance with applicable laws and the Company's Charter
 - Perform other duties as requested by the Chairperson.


4.7 Vote Counting Committee

- The AGM shall elect one or several members to the Vote Counting Committee upon the proposal of the Chairperson;
- Duties and Responsibilities of the Vote Counting Committee
 - Disseminate voting principles and regulations, and provide instructions on voting procedures
 - Count and record votes; prepare the Vote Counting Minutes and announce the results; transfer the minutes to the Chairperson for approval of the voting results;
 - Promptly notify the Secretariat of the voting results;
 - Review and report to the General Meeting any violations of the voting regulations or complaints regarding the voting results.

4.8 Shareholder Eligibility Verification Committee

- The Chairperson shall appoint one or several individuals to serve on the Shareholder Eligibility Verification Committee for the meeting. The Shareholder Eligibility Verification Committee shall consist of one (01) Head of the Committee and its members;
- Duties of the Shareholder Eligibility Verification Committee:
 - Verification of the eligibility and attendance status of shareholders and their authorized proxies;
 - The Head of the Shareholder Eligibility Verification Committee shall report the attendance status of shareholders to the AGM. If the meeting is attended by a sufficient number of shareholders and authorized proxies representing more

1400
CÔNG
ĐUỘ
MEX
TINH E



than 50% of the total voting shares, the AGM of the Company shall be convened and proceeded with;

- To participate in the counting of votes for other matters prior to the establishment of the Vote Counting Committee.

4.9 Making statements at the Meeting

4.9.1.Principle

- Discussions shall be conducted strictly within the allotted time and confined to the scope of the agenda items presented at the AGM.
- Delegates shall register their discussion topics in accordance with the prescribed procedures as follows:
 - Delegates wishing to raise questions may do so via the 'Discussion' section on the meeting interface of the E-voting system at the following link: [the ezgsm.fpts.com.vn](http://ezgsm.fpts.com.vn)

4.9.2.Addressing Shareholders' Inquiries

- Based on the inquiries raised by the delegates, the Chairperson or an appointee designated by the Chairperson shall address such inquiries;
- Due to time constraints, any inquiries that remain unanswered during the Meeting will be addressed by the Company subsequently through appropriate communication channels.

4.10 Voting to approve matters at the AGM

4.10.1 Principle

- All matters set forth in the Meeting agenda and content must be discussed and voted upon publicly by the AGM
- Delegates shall register for attendance at the venue specified in the Invitation Letter sent to all shareholders on the record list as of March 17, 2026, provided by VSDC. Upon successful registration with the Organizing Committee, delegates will be issued an account and password to log in and cast their electronic votes on all matters presented at the General Meeting via the following link: ezgsm.fpts.com.vn.
- In the event that a username, password, and/or other identification factors are lost, stolen, compromised, or suspected of being compromised, the Delegate must immediately notify the Company for the timely suspension of such credentials and security devices. The Delegate shall be solely held liable for any damages, losses, or risks arising from their own negligence or error.



- Shareholders may cast their votes remotely prior to the opening of the General Meeting. The Organizing Committee shall consolidate these votes, which will be included in the total number of shareholders attending and voting at the Meeting. Shareholders are required to cast their votes, sign, and clearly state their full names on the Voting forms available on the Company's website. Completed Voting form must be submitted to the Company no later than 15:00 on April 20, 2026, via one of the following methods:
 - Submit a scanned copy to email: codong@imexpharm.com using the email address officially registered in the Shareholder List provided by VSDC as of the record date of March 17, 2026
 - Or by post to: Administration Department - Imexpharm Pharmaceutical Joint Stock Company, at: No. 4, 30/4 Street, Ward 1, Cao Lanh City, Dong Thap Province, Vietnam

4.10.2 Electronic Voting

Forms of voting at the General Meeting:

- Voting shall be conducted by means of electronic voting and/or show of hands for the approval of the Meeting Agenda, the Meeting Regulation, the members of the Vote Counting Committee, the Minutes of the Meeting, the Resolution of the Meeting, and a number of other matters (if any).
- Voting shall be conducted by means of electronic voting for the approval of the Reports and Proposals submitted to the AGM for the adoption of the AGM Resolution.

4.10.3 Voting Methods

- When voting via the e-voting system, delegates shall select one of three options: 'Agree', 'Disagree', or 'Abstain' for each matter presented at the Meeting. Subsequently, delegates must click 'Submit Vote' to ensure their results are recorded by the e-voting system
- Other regulations regarding the electronic voting process
 - In the event that matters arise outside the pre-distributed Meeting agenda, Delegates may cast additional votes. If a Delegate does not perform the voting for such arising matters, it shall be deemed that the Delegate has not cast a vote on those specific matters
 - Delegates may modify their voting selections (but may not cancel their votes); this includes supplementary votes for matters arising outside the Meeting

433-
CP
IAM
ARM
THA



agenda. The online system shall only record and count the final voting results at the conclusion of each electronic voting period as prescribed in the Meeting's Regulations.

- E-voting period for matters subject to voting at the Meeting: Delegates may cast their votes from the completion of the meeting registration procedures until the Organizing Committee announces the conclusion of the electronic voting period for the respective voting items.
- Upon the conclusion of the voting period, the system shall no longer record any further electronic voting results from Delegates


4.10.4 Voting Rules

Each ordinary share shall entitle the holder to one (1) vote. Each attending Delegate represents one or more voting rights.

- As of the shareholder record date (17 March 2026), the total number of outstanding shares of the Company is 154,008,962 shares (excluding 33,800 treasury shares), equivalent to 154,008,962 voting rights.
- Matters subject to voting at the Meeting shall be approved only when favored by Delegates owning and/or representing more than 50% of the total votes of all Delegates attending and voting at the Meeting. Particularly, for specific matters as prescribed in Clause 1, Article 21 of the Company's Charter, an approval rate of at least 65% of the total votes of all attending and voting Delegates is required.
- Note: Regarding the approval of contracts or transactions as prescribed in Clauses 1 and 3, Article 167 of the Law on Enterprises 2020, Shareholders/Authorized Representatives with related interests in the parties to such contracts or transactions shall not have voting rights. These contracts or transactions shall only be approved if favored by Shareholders/Authorized Representatives representing at least 65% of the remaining total votes at the AGM (in accordance with Clauses 4, Article 167 of the Law on Enterprises 2020)

4.10.5 Recording of Voting Results

- At the Meeting, the AGM shall approve the Scrutineers (Vote Counting Committee)
- The Scrutineers are responsible for aggregating the voting results from Delegates attending in person and those casting their votes via the electronic voting system.
- The Scrutineers shall verify the number of 'Agree', 'Disagree', and 'Abstain' votes for each agenda item and shall be responsible for recording, tabulating, and reporting the voting results at the AGM.





4.11 Minutes and Resolutions of the AGM

All proceedings of the AGM must be recorded in the Minutes by the Meeting Secretaries. The Minutes must be read and approved before the adjournment of the Meeting.

5. Implementation

- All Delegates and invited guests attending the Meeting shall be responsible for full compliance with the provisions of these Regulations, the Company's current internal rules and management regulations, as well as all relevant legal provisions.
- Any matters not specifically provided for in these Regulations shall be governed by the Company's Charter, the Law on Enterprises 2020, and other applicable laws and regulations of the State

These Regulations shall take effect immediately upon approval by the AGM.

ON THE BEHALF OF
BOARD OF DIRECTORS
CHAIRPERSON

Recipients:

- 2026 AGM;
- Save: Admin, Board Secretary



SUNG MIN WOO



IMEXPHARM CORPORATION**SOCIALIST REPUBLIC OF VIETNAM**
Independence - Freedom - Happiness

No.: 01 /BC-HĐQT-IMP

Dong Thap, March 25, 2026


**REPORT AND ASSESSMENT OF THE ACTIVITIES OF
THE BOARD OF DIRECTORS IN 2025
ORIENTATION PLAN FOR 2026****I. BOARD OF DIRECTORS****1. Members of the Board of Directors**

The Board of Directors (BOD) of Imexpharm for the 2023–2027 term, as approved by the General Meeting of Shareholders, consists of 06 members, of whom 05 are non-executive members, 02 are independent members, and 02 are female members. The composition of Imexpharm's Board of Directors is diverse in terms of qualifications, age, expertise and experience, and at the same time meets the requirements on the number of independent board members applicable to listed companies.

The Chairman of Imexpharm's Board of Directors is a non-executive member and does not concurrently hold the position of General Director.

The list of members of the Board of Directors is as follows:

No.	Full name	Position on the BOD	Date of becoming/ceasing to be a BOD member	
			Appointment date	Dismissal date
1.	Mr. Sung Min Woo	BOD Chairman Non-executive member	First appointed: 30 October 2024	
2.	Mr. Chung Suyong	Independent Board member	First appointed: 28 April 2023	
3.	Mdm. Tran Thi Dao	Executive Board member	- First appointed: 29 July 2001 (BOD Chairwoman) - Second appointed: 17 May 2013 (BOD Vice Chairwoman) - Third appointed: 28 April 2023.	
4.	Ms. Han Thi Khanh Vinh	Non-executive Board member	- First appointed: 28 Apr 2018 - Second appointed: 28 Apr 2023.	



No.	Full name	Position on the BOD	Date of becoming/ceasing to be a BOD member	
			Appointment date	Dismissal date
5.	Mr. Truong Minh Hung	Non-executive Board member	- First appointed: 30 May 2020 - Second appointed: 28 April 2023.	
6.	Mr. Hoang Duc Hung	Independent Board member	First appointed: 19 December 2023	

Changes in the Board of Directors in 2025: There were no changes.

2. Activities of the BOD and BOD Committees in 2025

2.1. Activities of the BOD

In 2025, the BOD of Imexpharm Corporation fully performed its governance, strategic orientation and executive oversight functions in accordance with the law, the Charter and the Internal Corporate Governance Regulations, based on the principles of transparency, collective decision-making and accountability.

In 2025, the BOD of Imexpharm Corporation held a total of 10 meetings to consider, discuss and decide on matters within its authority. All BOD members attended all meetings, engaged actively in the discussions, analysing and voting on each agenda item, thereby ensuring that resolutions were adopted on a prudent and transparent basis and in the best interests of the Company.

The BOD focused on overseeing the implementation of the GSM's Resolutions, the timely payment of 2024 cash dividends, the selection of the independent auditor for 2025, the collection of shareholders' written opinions, and the monitoring of the progress of the Cat Khanh Pharmaceutical Plant Complex Project. At the same time, the BOD strengthened risk management, supervised the internal control system and enhanced the role of the Audit Committee in financial and compliance matters.

BOD meetings in 2025

No.	BOD member	Number of BOD meetings attended	Attendance rate
1	Mr. Sung Min Woo	10	100%
2	Mr. Chung Suyong	10	100%
3	Mdm. Tran Thi Dao	10	100%
4	Ms. Han Thi Khanh Vinh	10	100%
5	Mr. Truong Minh Hung	10	100%



No.	BOD member	Number of BOD meetings attended	Attendance rate
6	Mr. Hoang Duc Hung	10	100%

Resolutions and Decisions of the BOD issued in 2025


No.	Resolution/ Decision No.	Date	Subject matter
1	01/2025/NQ-HĐQT-IMP	26 February 2025	- Approving the plan for convening the 2025 Annual General Meeting of Shareholders of Imexpharm Corporation.
2	02/2025/NQ-HĐQT-IMP	10 March 2025	- Approval of Land Lease Payment to the Dong Thap Province Center for Investment and Infrastructure Development for the Implementation of the Cat Khanh Pharmaceutical Factory Complex - Imexpharm Corporation.
3	03/2025/NQ-HĐQT-IMP	03 April 2025	- Approval of the 2025 credit line through both unsecured and secured facilities at commercial banks, with a total value of VND 700 billion (Seven hundred billion dong). - Approval of assigning the General Director to select appropriate commercial banks and sign credit agreements for 2025, in alignment with the principle of financial efficiency optimization.
4	04/2025/NQ-HĐQT-IMP	03/04/2025	- Approval of the purchase of D&O insurance for 2025 and assign, authorise the General Director to carry out the contract execution and necessary procedures. - Approval of assigning and authorizing the Chairperson of the BOD to carry out the approvals for necessary procedures to purchase and maintain annual D&O insurance.
5	05/2025/NQ-HĐQT-IMP	14/05/2025	- Approval of the implementation of the Cat Khanh Pharmaceutical Factory Complex Project. - Approval of the authorization and assignment to the General Director to carry out certain tasks and procedures necessary for the implementation of the project.

384
 3 TY
 3 PH
 PH
 0NG



No.	Resolution/ Decision No.	Date	Subject matter
6	06/2025/NQ- HĐQT-IMP	21/05/2025	- Approval of the 2024 cash dividend payment pursuant to Article 5 of Resolution No. 01/2025/NQ-ĐHĐCĐ-IMP dated April 25, 2025 of the Annual General Meeting of Shareholders.
7	07/2025/NQ- HĐQT-IMP	04/06/2025	- Approval of the selection of KPMG Vietnam Co., Ltd. as the independent auditor to perform the review of interim financial information and the audit of the 2025 financial statements. - Approval of the authorization and assignment of the General Director to negotiate, decide on the terms, and sign the audit engagement contract with KPMG Vietnam Co., Ltd., and to carry out all related tasks.
8	08/2025/QĐ- HĐQT-IMP	21/07/2025	Decision on the dismissal of Mr. Nguyen An Duy - Deputy General Director cum Chief Financial Officer - pursuant to his Resignation letter
9	09/2025/NQ- HĐQT-IMP	15/08/2025	Approval of the exercise of subscription rights under the share issuance plan for existing shareholders of the associated company, Agimexpharm Pharmaceutical JSC., with a total expected investment amount of VND 30.1 billion.
10	10/2025/NQ- HĐQT-IMP	23/09/2025	- Approval of obtaining shareholders' approval by written resolution on matters under the authority of the General Meeting of Shareholders: (1) Cancellation of the 2026 Cash Bonus Program for Key personnel, as approved under Resolution No. 02/2023/NQ-DHĐCĐ-IMP dated December 19, 2023 of the General Meeting of Shareholders of Imexpharm Corporation; (2) Approval of the Share Issuance Plan under the Company's Employee Stock Ownership Plan (ESOP);

33-
CP
AM
RM
THA



During the year, the NCC held 01 meeting to review, assess and propose compensation, bonus and benefits policies for the Executive Board for 2026, based on 2025 KPI results and the Company's strategic orientation. These policies were developed on the principles of transparency, linkage to performance, management capability and long-term growth objectives.

In addition, all NCC members attended BOD meetings and contributed their views on medium- and long-term senior personnel strategy. Through its specialised activities and independent oversight, the Committee helped ensure that decisions on appointments, remuneration and benefits were made objectively, prudently and in the long-term interests of the Company and its shareholders.

II. BOD' assessment report on business operations in 2025


1. Overview of the implementation of the General Meeting of Shareholders' Resolutions

During 2025, the Board of Directors (BOD) convened one Annual General Meeting of Shareholders (AGM) and conducted one written shareholders' resolution. The procedures for organizing the AGM and obtaining shareholders' written opinions were carried out carefully and in strict compliance with the Law on Enterprises, the Company's Charter, the Internal Governance Regulations, and other relevant legal provisions.

The implementation status of the AGM Resolutions is summarized as follows:

Content	Result
I. 2025 production and business targets	
Gross revenue: VND 2,981,0 billion	Imexpharm's gross revenue in 2025 reached VND 2,914.3 billion, fulfilling 97.8% of the annual target and representing a 16.0% increase compared to 2024
Net revenue: VND 2,649.0 billion	Net revenue reached VND 2,441.1 billion, achieving 92.2% of the annual target and increasing by 10.7% year-on-year
Profit before tax (PBT): VND 493.5 billion	Profit before tax reached VND 446.2 billion, achieving 90.4% of the annual target and increasing by 10.4% year-on-year.

CHỖ ĐÓNG
 CHỮ ĐÓNG
 CHỮ ĐÓNG
 CHỮ ĐÓNG
 CHỮ ĐÓNG



During the year, the NCC held 01 meeting to review, assess and propose compensation, bonus and benefits policies for the Executive Board for 2026, based on 2025 KPI results and the Company's strategic orientation. These policies were developed on the principles of transparency, linkage to performance, management capability and long-term growth objectives.

In addition, all NCC members attended BOD meetings and contributed their views on medium- and long-term senior personnel strategy. Through its specialised activities and independent oversight, the Committee helped ensure that decisions on appointments, remuneration and benefits were made objectively, prudently and in the long-term interests of the Company and its shareholders.

II. BOD' assessment report on business operations in 2025

1. Overview of the implementation of the General Meeting of Shareholders' Resolutions

During 2025, the Board of Directors (BOD) convened one Annual General Meeting of Shareholders (AGM) and conducted one written shareholders' resolution. The procedures for organizing the AGM and obtaining shareholders' written opinions were carried out carefully and in strict compliance with the Law on Enterprises, the Company's Charter, the Internal Governance Regulations, and other relevant legal provisions.

The implementation status of the AGM Resolutions is summarized as follows:

Content	Result
I. 2025 production and business targets	
Gross revenue: VND 2,981,0 billion	Imexpharm's gross revenue in 2025 reached VND 2,914.3 billion, fulfilling 97.8% of the annual target and representing a 16.0% increase compared to 2024
Net revenue: VND 2,649.0 billion	Net revenue reached VND 2,441.1 billion, achieving 92.2% of the annual target and increasing by 10.7% year-on-year
Profit before tax (PBT): VND 493.5 billion	Profit before tax reached VND 446.2 billion, achieving 90.4% of the annual target and increasing by 10.4% year-on-year.

140
 CÔNG
 ĐỤC
 IME
 TỈNH




Content	Result
EBITDA: VND 635.0 billion <i>(Earnings Before Interest, Taxes, Depreciation and Amortization)</i>	EBITDA in 2025 reached VND 567.2 billion, achieving 89.3% of the annual target and growing by 8.9% year-on-year.
II. 2024 profit distribution and dividend plan	
Cash dividend payment at a rate of 5% of par value based on the number of outstanding shares	On July 9, 2025, the Company completed the payment of over VND 77 billion in cash dividends for the fiscal year 2024
Allocation to the reward and welfare fund at 14.03% of distributable profit after tax	The Company set aside VND 45 billion for the reward and welfare fund (*)
III. 2025 remuneration and bonus plan for the BOD and its committees	
Remuneration and operating expenses of the BOD and its Committees for 2025: 2% of profit before tax, calculated prior to the actual expenses incurred for the BOD and its Committees.	The Company allocated remuneration and operating expenses for the BOD and its Committees for 2025 in accordance with the approval of the General Meeting of Shareholders, totaling VND 9.1 billion.
IV. Selection of an independent auditor for the 2025 financial statements	
Authorization of the Board of Directors to select one of the four independent auditing firms for the 2025 Financial Statements.	Pursuant to the proposal submitted by the General Director and after reviewing the recommendation of the Audit Committee, the Board of Directors authorized the General Director to execute Audit Service Contract No. 01/HĐKT dated July 4, 2025 with KPMG Limited (Vietnam).
V. Addition of business lines	
Addition of a New Business Line: - Business Code 6810: Real estate business; trading of land use rights owned, used or leased.	The Company completed the registration procedures in accordance with the Certificate of Enterprise Registration Amendment dated May 21, 2025 issued by the Department of Finance of Dong Thap Province.

 038
 G T
 C P
 (PH
 ĐON




Content	Result
<p>- Details: Real estate business activities in accordance with Clause 3, Article 10 of the 2023 Law on real estate business.</p>	<p>Accordingly, Clause 1, Article 4 of the Company's Charter regarding the Company's business lines was amended and supplemented to reflect the above addition of business lines.</p>
<p>VI. Change in the maximum foreign ownership limit</p>	
<p>The maximum foreign ownership ratio in Imexpharm Corporation shall not exceed 77.96% of the Company's charter capital.</p>	<p>Pursuant to Official Letter No. 2171/UBCK-PTT dated June 4, 2025 issued by the State Securities Commission of Vietnam (SSC), the Company's maximum foreign ownership ratio is 77.96% of its total charter capital.</p> <p>Accordingly, Clause 8, Article 6 of the Company's Charter governing the foreign ownership ratio was amended and supplemented to reflect the above change in the maximum foreign ownership limit.</p>
<p>VII. Amendments and supplements to the Company's Charter and the Internal regulations on Corporate governance</p>	
<p>Amendments to the Company's Charter and the Internal regulations on Corporate governance</p>	<p>Completion of amendments to the Company's Charter and the Internal regulations on Corporate governance</p>
<p>VIII. Purchase of Directors' and Officers' Liability insurance (D&O insurance) for 2025</p>	
<p>The AGM assigned the BOD to carry out the necessary procedures for the annual purchase of Directors' and Officers' (D&O) liability insurance and to proactively renew the policy upon its expiration.</p>	<ul style="list-style-type: none"> ▪ The General Director executed Directors' and Officers' (D&O) Liability Insurance Policy No. VNDAOA10330125 dated April 3, 2025 with Chubb Insurance Vietnam Co., Ltd. ▪ Policy term: 12 months, renewable annually ▪ Total limit of liability: USD 10,000,000 ▪ Insurance premium: USD 12,500 (exclusive of VAT)
<p>IX. Cancellation of the 2026 cash bonus program for key personnel</p>	

1433-C
Y CP
HÀM
ARM
3 THÁP



Content	Result
The General Meeting of Shareholders, through a written resolution, approved the cancellation of the 2026 Cash Bonus Program for Key Personnel.	Cancellation of the Cash Bonus Program for Key Personnel in 2026 as approved under Resolution No. 02/2023/NQ-ĐHĐCĐ-IMP dated December 19, 2023 of the General Meeting of Shareholders.
X. Approval of the share issuance plan under the Employee Stock Ownership Plan (ESOP)	
The General Meeting of Shareholders, through a written resolution, approved the issuance of more than 1.55 million ESOP shares at a price of VND 5,000 per share, subject to a one-year transfer restriction period.	The Board of Directors will determine an appropriate timing for the implementation of the ESOP for employees in 2026.

() In addition, in 2025, the Company allocated VND 103,730,532,105 from undistributed profit after tax to supplement the Reward and Welfare Fund for the implementation of the 2025 Long-term Cash Incentive Program, in accordance with Resolution No. 02/2023/NQ-ĐHĐCĐ-IMP dated December 19, 2023 of the General Meeting of Shareholders.*

2. Assessment of business performance


In 2025, the Vietnamese pharmaceutical market continued to grow amid rising demand for high-quality medicines. However, competition intensified, and regulatory as well as manufacturing compliance requirements became increasingly stringent.

Aligned with the strategic direction approved by the Board of Directors and under the proactive and consistent leadership of the Board of Management, Imexpharm continued to outperform overall industry growth. For the year ended 2025, the Company recorded gross revenue of VND 2,914 billion, representing a 16.0% year-on-year increase and achieving 98% of the annual target. Net revenue reached VND 2,441 billion, up 10.7% compared to 2024. These results reflect the effectiveness of the Company's strategy to focus on high-value products, expand market coverage, and optimize distribution channels.

Gross profit in 2025 amounted to VND 1,002 billion, up 17.1% year-on-year, with the gross profit margin improving to 41.0%. Tight control of cost of goods sold, enhanced manufacturing efficiency, and effective inventory management strengthened profitability and established a solid foundation for sustainable growth. Profit before tax reached VND



446 billion, increasing by 10.4% compared to the previous year, while EBITDA totaled VND 567 billion, up 8.9%, with the EBITDA margin maintained at 23.2%.



In terms of revenue structure, both the ETC and OTC channels recorded positive growth. ETC revenue increased by 11.8% year-on-year, driven by rising demand for EU-GMP-certified products and a portfolio shift toward high-value and high-technology medicines. The OTC channel grew by 18.3%, marking a clear recovery following a period of adjustment. Notably, revenue from major pharmacy chains surged by 75.8% year-on-year, raising their contribution to 13.8% of total OTC revenue.

In 2025, Imexpharm continued to reinforce its core competitive strengths through innovation and product development. The Company launched 25 new products, exceeding its annual target of 16 products, while maintaining 157 ongoing R&D projects. Notably, the successful commercialization of IMECEP – the first EU-GMP-certified “first generic” antibiotic in Vietnam – not only represented a significant technological milestone but also strengthened Imexpharm’s position in the next-generation antibiotic segment. The Company maintained its No. 1 position in antibiotic manufacturing and distribution for the third consecutive year.

In parallel with its domestic operations, the Company further expanded its international footprint, obtaining 28 marketing authorizations in Europe for 11 products, while accelerating product registrations and distribution partnerships in new markets.

Additionally, Imexpharm completed key legal procedures for the Cat Khanh Pharmaceutical Manufacturing Complex Project and officially commenced Phase 1 investment in infrastructure and warehousing systems, laying the foundation for long-term production capacity expansion.

The Board of Directors and the Board of Management have demonstrated proactive, flexible, and decisive leadership, enabling the Company not only to sustain stable short-term growth but also to strengthen its foundation for the next phase of development. These

I.A.O.C.
 ÔN
 UỐ
 MEX
 V H E





achievements provide a solid platform for Imexpharm to pursue more ambitious growth objectives while creating sustainable long-term value for shareholders and stakeholders.

3. Internal governance activities

In 2025, under the direction of the Board of Directors, Imexpharm's internal governance framework continued to be strengthened in a professional, transparent, and fully compliant manner, in accordance with applicable laws, the Company's Charter, and its Internal Regulations on Corporate Governance.

The governance system was operated consistently, enhancing management discipline, strengthening accountability, and effectively supporting business operations amid the Company's ongoing expansion and the implementation of key strategic projects.

During the year, the Company successfully convened its Annual General Meeting of Shareholders and conducted written shareholder resolutions for matters within its authority, ensuring strict, transparent, and well-structured procedures. The continued application of the electronic voting (e-voting) system, together with timely and comprehensive information disclosure, facilitated shareholder participation and further improved governance quality and investor engagement.

The Board of Directors maintained effective oversight through regular, ad hoc, and thematic meetings, focusing on monitoring the implementation of resolutions, supervising business performance, and overseeing major expansion and investment initiatives.

Risk management and compliance functions were further enhanced through the maintenance of a comprehensive enterprise risk management framework, regular updates to the Company's key risk register, and cascading risk management responsibilities to relevant departments. Internal audit functions were also carried out during the transitional period, contributing to stronger internal controls and risk mitigation.

In addition, the Board's committees, including the Audit Committee and the Nomination and Compensation Committee, operated effectively, providing active support in financial oversight, performance evaluation of management, and senior human resource governance. The Board of Management assesses that, in 2025, Imexpharm's internal governance system effectively met the requirements of its new development phase, ensuring balanced and sustainable benefits for shareholders and other stakeholders.

4. Environmental and social performance

In 2025, the BOD provided strategic direction and recognized the efforts of the Board of Management for implementing environmental management practices under a proactive risk governance approach, fully integrated into the Company's operational strategy and long-term development plans.

3844

TY

PH

PHA

ĐNG





Environmental risks arising from pharmaceutical manufacturing activities were systematically identified, assessed, and controlled from the planning and technology selection stages through production operations and post-production monitoring. This comprehensive approach ensured regulatory compliance while minimizing potential impacts on the environment and local communities.

In manufacturing operations, the Company continued to strengthen raw material management and advance sustainable technology improvements. The expanded application of Enzymatic technology in antibiotic production helped reduce the use of chemical solvents, strictly control potentially hazardous impurities, and enhance resource efficiency. This approach not only improved product quality, safety, and therapeutic effectiveness, but also protected employee health and aligned with the pharmaceutical industry's sustainability trends.

In parallel, Imexpharm implemented integrated measures to conserve and optimize the use of energy, water, and natural resources through equipment upgrades, improvements to the Heating, Ventilation and Air Conditioning (HVAC) system, as well as enhancements to Cleaning-in-Place (CIP) and Sterilization-in-Place (SIP) systems, LED lighting enhancements, and gradual investment in rooftop solar power systems. Waste, emissions, and wastewater management were conducted in strict compliance with applicable regulations, supported by reputable waste treatment partners and regular environmental monitoring to proactively mitigate risks and meet prevailing environmental standards.

Beyond environmental initiatives, the Board also recognized the Company's efforts in fulfilling its social responsibilities through human capital development and community engagement. Imexpharm maintained a safe working environment, emphasized professional training and capacity building, safeguarded occupational health, and implemented impactful community, healthcare, and educational programs.

The BOD assesses that the Company's consistent balance between economic growth, environmental stewardship, and social responsibility in 2025 has established a solid foundation for Imexpharm's sustainable development in the years ahead.

III. Assessment of the Board of Management

Pursuant to the Company's Charter and the Internal Regulations on Corporate Governance, the BOD conducted oversight of the General Director and the Board of Management in 2025 by monitoring the implementation of resolutions of the General Meeting of Shareholders and the BOD, as well as reviewing the Company's business performance, as detailed below:

1. Supervisory approach

- The Board of Directors convened regular quarterly meetings, ad hoc meetings, and



thematic sessions to review and evaluate operational reports, directly question the General Director and the Board of Management regarding the achievement of business targets, market development, product portfolio expansion, partnership initiatives, and to discuss the Company's medium- and long-term strategic vision.

- The Board directed the development and periodic review of a Key Performance Indicator (KPI) framework applicable to each member of the Board of Management. This KPI system serves as the basis for quarterly, semi-annual, and annual performance evaluations, and is closely linked to the remuneration and incentive policies applicable to the Board of Management.

The Board of Directors supervised the General Director and the Board of Management in the implementation of the following key matters:

- Oversight of the independent audit of the 2024 Financial Statements as at December 31, 2024.
- Review and supervision of the preparation of the 2025 business plan for submission to the AGM for approval.
- Coordination with the Board of Management to successfully convene the 2025 AGM on April 25, 2025.
- Supervision of the timely payment of 2024 dividends to shareholders. The 2024 dividend, approved by the AGM at a rate of 5% of charter capital in cash, was paid on July 9, 2025, within 30 days from the record date and within three months from the date of the AGM.
- Continued strengthening of risk management and compliance activities.
- Promotion of human resource development and internal training, particularly within key professional functions.
- Authorization of the General Director to execute the 2025 audit engagement contract with KPMG Limited – Branch, ensuring selection in accordance with the list and criteria approved by the AGM, for the audit of the 2025 annual Financial Statements and the review of the 2025 semi-annual Financial Statements.
- Coordination with the Board of Management to conduct a written shareholder resolution in October 2025.
- Supervision of the implementation of the Cat Khanh Pharmaceutical Manufacturing Complex Project. The Company completed the licensing procedures for the project and established Imexpharm Corporation - Cat Khanh Branch. Phase 1 investment of the project was commenced.



- Oversight of the effective execution of the 2025 business and production targets in accordance with the AGM's resolutions.

2. Conclusion

The General Director, Deputy General Directors, and the management team effectively and responsibly executed the 2025 business and production objectives, enabling the Company to achieve strong growth and nearly fulfill its gross revenue target amid a challenging market environment. At the same time, the Board of Management strictly complied with the Company's Charter, Internal Regulations, and the resolutions and decisions of the General Meeting of Shareholders and the BOD throughout 2025.

IV. RELATED PARTY TRANSACTIONS - REMUNERATION, SALARIES, BONUSES AND OTHER BENEFITS OF INSIDERS

1. Related-party transactions


In 2025, the Company entered into transactions with Agimexpharm Pharmaceutical Joint Stock Company, an associate in which Imexpharm holds 31.56% of the shares and which is also a related party of an insider, as Ms. Tran Thi Dao – General Director of Imexpharm – serves as a member of the BOD of Agimexpharm.

(Detailed information on specific transactions with Agimexpharm is presented in Note 34 "Significant transactions with related parties" to the Notes to the Financial Statements – Audited Financial Statements for 2025 – page 47)

- The transaction contracts with Agimexpharm Pharmaceutical Joint Stock Company were approved by the Board of Directors for signing in accordance with its authority and were fully disclosed. The nature of these transactions is that Agimexpharm performs processing and manufacturing of certain products for Imexpharm under contract. The prices and terms of the transactions are transparent and consistent with market conditions, and there are no preferential terms or unusual clauses in the transaction contracts.
- In addition, in 2025, Imexpharm exercised its rights to subscribe for additional shares issued to existing shareholders of Agimexpharm, with a total transaction value of VND 30.1 billion. This transaction was analysed and evaluated by the BOD and approved in accordance with its authority under Resolution No. 09/2025/NQ-HĐQT-IMP dated 15 August 2025.

During the year, the Audit Committee, on behalf of the Board of Directors, also directed the review and closely monitored the Company's transactions with related parties.

2. Remuneration, salaries, bonuses and other benefits of the Board of Directors and Board Committees





The remuneration of the Board of Directors and BOD Committees is approved annually by the General Meeting of Shareholders. The remuneration policy for each member is determined by the Board of Directors, based on agreements with such members and on recommendations from the Nomination and Compensation Committee, taking into account their respective contributions to the BOD and the Company.

The total pool of expenses, remuneration, salaries and bonuses of the BOD and BOD Committees in 2025 is as follows:

No.	Item	Amount (VND)
1	Remuneration and bonuses of the BOD carried forward from the previous year not yet paid	13,553,563,317
2	Remuneration and bonuses accrued for 2025	9,107,096,696
3	Remuneration, bonuses and expenses paid in 2025	19,823,807,101
4	Remuneration and bonuses carried forward to 2026	2,836,852,912

(Details of remuneration, salaries and bonuses of each member of the Board of Directors, BOD Committees, and other insiders are presented in Note 34 "Major transactions with related parties" - Notes to the Financial Statements - Audited Financial Statements for 2025 - pages 47-48)

V. PLANS AND STRATEGIC DIRECTIONS OF THE BOD FOR 2026

Building on the achievements of 2025, the Board of Directors intends to submit to the General Meeting of Shareholders the following business and production plan for 2026:

(Unit: VND billion)

Indicator	2025 Actual	2026 Plan	2026 Plan vs. 2025 Actual (%)
Gross revenue	2,914	3,200	9.8%
Profit before tax	446	502	12.6%
EBITDA	567	637	12.3%

Entering 2026, the Board of Directors has outlined the following key priorities:

1. Pursuing sustainable growth and enhancing revenue quality

- Gross revenue for 2026 is projected at VND 3,200 billion, representing a 9.8% increase compared to 2025. The Company aims to expand its market share in Northern Vietnam through the establishment of a new Hai Phong Branch.
- The Company will focus on developing high-technology product portfolios, prioritizing high-value EU-GMP-standard products, increasing the proportion of higher-margin product groups, and optimizing the revenue mix between the ETC and OTC channels.

2. Enhancing operational efficiency and improving profitability





- Profit before tax is targeted at VND 502 billion, up 12.6%, driven by disciplined cost control, production optimization, and productivity enhancement at EU-GMP-certified manufacturing facilities.
- Planned EBITDA is VND 637 billion, an increase of 12.3%, further strengthening the Company's ability to generate cash flow from core operations.
- The Company will continue to optimize raw material costs, improve supply chain management efficiency, and maximize utilization of existing manufacturing capacity.

3. Strengthening market position and expanding distribution channels

- Imexpharm will maintain its strong position in the ETC channel while accelerating growth in high-technology and specialized pharmaceutical segments.
- In the OTC channel, the Company will expand market coverage through enhanced cooperation with pharmacy chains and retail networks, alongside continued digitalization of distribution management.
- Efforts will also focus on improving demand forecasting capabilities, optimizing inventory management, and enhancing market responsiveness.

4. Accelerating strategic investments and long-term operational optimization

- The Company will continue developing the Cat Khanh Pharmaceutical Manufacturing Complex Project, establishing a foundation for medium- and long-term growth.
- Investment in R&D will be further intensified, with expanded focus on key therapeutic areas such as cardiovascular diseases, diabetes, gastrointestinal disorders, and other high-demand chronic conditions, in addition to leading antibiotic and cough product segments.
- Digital transformation initiatives across manufacturing, finance, and distribution systems will be strengthened to enhance productivity and improve data transparency.

5. Enhancing corporate governance and sustainable development

- The Company will continue refining its risk management and internal control systems, aligning corporate governance practices with advanced standards.
- ESG standards will be further strengthened to enhance transparency and reinforce trust among shareholders and investors.
- Imexpharm will also focus on developing succession planning capabilities, strengthening management competencies, and fostering a high-performance and innovation-driven corporate culture across the organization.

4433
Y CP
HÀM
ARM
3 THP



The 2026 plan is built on the positive results achieved in 2025, and reflects a prudent yet sustainable growth orientation amid the fiercely competitive pharmaceutical market and increasingly stringent compliance and ESG requirements. It sets profit and EBITDA growth targets that outpace revenue growth, aligned with the strategy to develop a higher value-added product portfolio, optimize resources, and maintain financial discipline, demonstrating that the Board of Directors focuses not only on the quality of growth but also on transparent and sound corporate governance as a key pillar of competitiveness. On that basis, the Company not only expands its scale of operations but also elevates its governance standards and financial strength, thereby enhancing sustainable value for shareholders and reinforcing its position as a leading pharmaceutical enterprise in Vietnam.

**ON BEHALF OF THE
BOARD OF DIRECTORS
CHAIRMAN**



SUNG MIN WOO





REPORT ON BUSINESS AND FINANCIAL PERFORMANCE IN 2025
OPERATIONAL PLAN OF THE EXECUTIVE BOARD FOR 2026


I. Macroeconomic context and pharmaceutical industry business environment in 2025

1. Global macroeconomic environment and outlook

The global economy in 2025 remained relatively stable as inflation continued to ease and monetary policies in many major economies gradually shifted toward a more neutral stance. However, growth remained uneven due to geopolitical tensions, the restructuring of global supply chains, and public debt pressures.

According to the International Monetary Fund (IMF), global GDP growth reached 3.3% in 2025 and is projected to remain at the same level in 2026. Meanwhile, the Organization for Economic Co-operation and Development (OECD) forecasts that global growth will slow to 2.9% in 2026, compared with an estimated 3.2% in 2025. In particular, the U.S. economy is expected to decelerate from 2% to 1.7%, while Europe and China are likely to face slower growth.

Vietnam and ASEAN-5 Economic Growth (2018–2025) and 2026 Forecast



Source: IMF, NSO

Against this backdrop, the global pharmaceutical industry continued to record stable growth, with a medium-term CAGR of approximately 5-8% (according to IQVIA), driven by increasing demand for chronic disease treatments and population ageing. However, cost-containment pressures in developed markets and the wave of patent expirations during the 2025–2030 period are intensifying competition in the generic and biosimilar segments, while also raising requirements for manufacturing standards and supply chain governance.






2. Vietnam macroeconomic environment and outlook

In 2025, Vietnam recorded GDP growth of 8.02%, among the highest in the Asia-Pacific region. The size of the economy reached approximately USD 514 billion, while GDP per capita increased to USD 5,026. Average inflation was maintained at 3.3%, below the target of 4.5%, contributing to a stable investment environment and favorable capital costs. Total import-export turnover exceeded USD 930 billion, reinforcing Vietnam’s important role in regional supply chains.


The Government continues to promote a shift in governance from a management-oriented approach to a development-facilitating approach, positioning science and technology, innovation, and digital transformation as key drivers of long-term growth. The year 2026 is identified as the starting point of a new development phase aligned with the orientation of the 14th National Party Congress, with the objective of achieving breakthroughs in institutional reforms, improving the investment environment, and effectively harnessing new growth drivers.

During the 2026–2030 period, Vietnam aims to maintain average GDP growth of around 10% per year or higher, with the goal of increasing GDP per capita to approximately USD 8,500 by 2030. At the same time, Vietnam aims to upgrade its economic structure, with the manufacturing and processing sector targeted to account for approximately 28% of GDP, while the digital economy is projected to contribute around 30% of GDP by 2030. These targets reflect Vietnam’s strategic transition from a processing-and assembly-based growth model toward one driven by high technology, innovation, and higher domestic value creation.

Vietnam CPI and Core Inflation (2017–2025)



Production Index of Pharmaceuticals, Chemicals and Medicinal Materials vs. Vietnam Industrial Production Index (2017 - 2025)



Source: NSO

N: 1 A
CÔN
DUC
IME
TINH



3. Business environment of Vietnam's pharmaceutical industry in 2025

In 2025, Vietnam's pharmaceutical industry continued to maintain positive growth momentum amid expanding economic activity and an increasingly transparent and standardized regulatory framework. According to IQVIA, during the 2023–2025 period, the market maintained an average growth rate of approximately ~8%, with estimated revenue reaching ~USD 9 billion. Market expansion has been driven not only by increased consumption but also by a gradual shift toward higher-value pharmaceutical products.


The market structure continues to be dominated by the retail channel (OTC), accounting for approximately 61% of total revenue and growing at 7%, supported by the expansion of modern pharmacy chains and growing consumer focus on self-care and preventive healthcare. The hospital channel (ETC) accounts for around 39% of total revenue, growing at 3%, supported by rising health insurance coverage (95.15% of the population), improvements in healthcare infrastructure, and increasingly professional centralized procurement mechanisms. Notably, treatment demand is shifting in line with the evolving disease burden structure, as non-communicable diseases (NCDs) now account for over 70% of the national disease burden, leading to increased demand for chronic disease treatments and specialty medicines.

From a supply perspective, Vietnam's domestic pharmaceutical manufacturing capacity continued to strengthen and upgrade its standards. As of the end of 2025, Vietnam had:

- 266 pharmaceutical manufacturing facilities certified with WHO-GMP
- 34 manufacturing facilities meeting EU-GMP or equivalent standards
- Approximately 1,700 hospitals nationwide, with an average growth rate of around 8% per year since 2020
- Total health insurance-covered medical visits increasing by around 5% annually, while health insurance expenditures have risen by approximately 11% per year since 2020

These indicators reflect improvements in manufacturing standards and competitiveness among domestic pharmaceutical companies, while also demonstrating the continuous expansion of the domestic healthcare market. At the same time, they highlight increasing requirements for pharmaceutical supply chain management, particularly given that Vietnam's domestic API self-sufficiency remains limited. As a result, the pharmaceutical industry continues to rely heavily on imported raw materials and remains sensitive to exchange rate fluctuations, logistics costs, and global supply chain disruptions.

The year 2025 also marked significant progress in regulatory reforms within the pharmaceutical sector. The implementation of the amended Law on Pharmacy, together with Decree No. 163/2025/ND-CP and related guiding circulars, has standardized



038
IG T
C F
XPH
DÓN



procedures for drug registration, importation, quality testing, and regulatory supervision. At the same time, administrative reform has been actively promoted, with nearly 40% of administrative procedures in the pharmaceutical sector reviewed and streamlined, helping to shorten processing times and reduce compliance costs for businesses. According to the Ministry of Health, as of November 2025, the online regulatory system had processed 8,378 applications for the importation of medicines and pharmaceutical ingredients, 877 applications for approval of drug advertising content, and 122 applications for GSP certification assessments.

Alongside institutional reforms, the pharmaceutical market supervision model is increasingly shifting toward post-market surveillance supported by digital platforms. The adoption of electronic prescriptions, electronic invoices, and QR-code-based traceability systems is helping to standardize data and enhance transparency across the pharmaceutical supply chain. The rate of detected counterfeit medicines declined to 0.024%, compared with 0.06% in 2024, reflecting the effectiveness of the new regulatory framework while also raising compliance standards and accelerating the industry's natural consolidation process.


II. Business Performance

1. Business Results in 2025



Unit: VND billion

No.	Indicators	Actual 2024	Actual 2025	Target 2025	% Growth	Actual vs Target (%)
1	Gross Revenue	2,512.8	2,914.3	2,981.0	16.0%	97.8%
2	OTC Channel	1,074.6	1,271.4	1,248.4	18.3%	101.8%
3	ETC Channel	1,377.5	1,540.5	1,634.3	11.8%	94.3%
4	Net Revenue	2,205.1	2,441.1	2,649.0	10.7%	92.2%
5	Profit Before Tax	404.2	446.2	493.5	10.4%	90.4%
6	EBITDA	520.8	567.2	635.0	8.9%	89.3%
7	EBITDA Margin	23.6%	23.2%	24.0%	-0.4%	96.7%

Gross revenue
(Unit: VND billion)




Net revenue
(Unit: VND billion)



1433
Y C
'HÀM
IARN
G TH

In 2025, Imexpharm recorded strong growth in both gross revenue and net revenue, outperforming the overall growth rate of the pharmaceutical industry. Gross revenue reached VND 2,914.3 billion, representing a 16.0% increase compared with 2024 and achieving 97.8% of the annual target, significantly higher than the domestic pharmaceutical peers' average growth of approximately 11%. Net revenue amounted to VND 2,441.1 billion, up 10.7% year-on-year and achieving 92.2% of the annual target, driven by growth across both the ETC and OTC channels.

Profit before tax (Unit: VND billion)



Gross profit increased by 17.1% year-on-year, significantly outpacing the growth of net revenue, supported by effective cost management, as cost of goods sold (COGS) increased by only 6.7%. This performance reflects the Company's efforts to improve inventory management, enhance production planning, and promote continuous manufacturing operations to optimize plant capacity. As a result, the gross profit margin improved to 41.0% (compared with 38.8% in 2024), reflecting stronger production efficiency and reinforcing the Company's profitability.

Profit before tax (PBT) reached VND 446.2 billion, representing a 10.4% increase compared with 2024 and achieving 90.4% of the annual target. This growth was lower than the increase in gross profit as the Company accelerated the restructuring of its sales network, expanded market coverage, and increased investment in digitalization across most stages of its business operations, leading to a 22.4% year-on-year increase in selling, administrative and general expenses. Nevertheless, maintaining double-digit PBT growth demonstrates that the Company's core operational efficiency remained resilient, while also reflecting a proactive willingness to incur short-term costs to build a foundation for long-term growth.

EBITDA (Unit: VND billion)



EBITDA reached VND 567.2 billion, representing an 8.9% increase compared with 2024 and achieving 89.3% of the annual target.

The EBITDA margin in 2025 stood at 23.2%, slightly lower than 23.6% in 2024 and below the 24.0% target, mainly due to short-term cost pressures arising from the expansion of business operations and increased investments in systems, human resources, and technology. Nevertheless, the Company continued to maintain effective operational cost control and stable production efficiency, reflecting its strategic focus on sustainable growth rather than short-term profit maximization.

2. Performance by Business Segment

Manufacturing

Production Output by Manufacturing Plant (Product Units)

Manufacturing Plants	Production Output 2025 sv 2024
IMP1	+9%
IMP2	+5%
IMP3	+26%
IMP4	+31%
Total	+11%

Sales Volume and Revenue by Manufacturing Plant (2025 vs. 2024)




In 2025, the Company successfully brought into operation the lyophilized powder production line (Line 1) at IMP4 Plant and the multi-dose powder production line at IMP2, contributing to enhanced manufacturing capacity and improved ability to meet market demand.

Imexpharm's manufacturing operations continued to be optimized, focusing on improving operational efficiency and cost control, in line with the Company's strategy of prioritizing high-technology and higher value-added products. The overall production loss rate improved compared with the previous year, decreasing by 11.1% compared with 2024, reflecting the effectiveness of process standardization, technical improvements, and the greater stability of newly commissioned production lines. The Company aims to further reduce the average loss rate in the coming years in order to optimize production costs and enhance profit margins.

Labor productivity (product units per working hour) increased by 5.5% in 2025 compared with 2024. This result reflects the effectiveness of the Company's manufacturing restructuring initiatives, systematic workforce training, and the application of digitalization.

1. AD
 CÔNG
 ĐUỘ
 MEX
 TỈNH E




in production management, enabling Imexpharm to expand manufacturing capacity while maintaining operational discipline and product quality, particularly as the product portfolio increasingly shifts toward injectables and high-technology pharmaceuticals.

To support revenue growth and prepare for potential orders, plant-level performance also improved significantly. Production output increased across all manufacturing plants, with IMP3 and IMP4 recording strong production output growth of 26% and 31%, respectively, while IMP1 and IMP2 increased by 9% and 5%, bringing the Company's total production output growth to 11% compared with 2024.

In terms of sales revenue and sales volume by plant, IMP4 recorded the highest growth rate, driven by the shift toward higher-value product segments and more effective capacity utilization at the Company's key manufacturing facilities.

Sales



Revenue from the ETC channel increased by 11.8% year-on-year, reflecting continued growth in demand for EU-GMP certified products. Growth in the ETC channel was driven by high-value and technology-intensive medicines, such as multi-dose powder formulations and lyophilized powder for injection, among others.

Meanwhile, OTC channel revenue recorded an 18.3% increase, with the number of customers expanding by 6% compared with the previous year, reflecting the strong recovery of the retail channel following the challenging period of 2023–2024. This result not only demonstrates the strengthening of the Company's market position but also enabled the OTC channel to exceed its annual target, achieving 101.8% of the plan. Growth was recorded across all business regions, with the Northern region leading at 51% year-on-year growth. Notably, revenue from major pharmacy chains increased by 75.8%, raising their contribution to 13.8% of total OTC revenue (from 9% in 2024). This expansion further enhanced market coverage and reinforced the role of modern distribution channels in Imexpharm's growth strategy.

384
 3 T
 > P
 PH
 3NG





Marketing and brand building

In 2025, Imexpharm implemented 59 diverse marketing activities nationwide, including group presentations, expert insights, hospital seminars, scientific conferences, and factory visits, with a strong focus on engaging healthcare professionals (HCPs). These programs reached approximately 6,000 physicians, contributing to increased brand awareness and reinforcing the Company's position within the medical community.

The Company organized a series of scientific seminars under the theme "*Advances in Corticosteroid Anti-inflammatory Therapy – Prednisolone ODT (Orally Disintegrating Tablet)*", including nine in-person seminars and one online conference. Following its launch, Predni-ODT was rapidly introduced to approximately 4,600 pharmacies and attracted nearly 4,000 new customers, significantly expanding the product's market coverage.

Imexpharm also maintained an active presence within the medical community through specialized seminar series and its annual ImexForum scientific program. In 2025, ImexForum was held in Hanoi for the first time, attracting nearly 300 healthcare professionals, marking an important milestone in the Company's strategy to expand its presence in the Northern market. In addition, the Company participated in and supported several prestigious scientific conferences, including the 41st National Ear, Nose and Throat (ENT) Conference, the National Pulmonology Scientific Conference (VILA 2025), and conferences organized by the Vietnam Pharmaceutical Association.

In the retail channel, Imexpharm served as a Diamond Sponsor at the Retail Operations & Partners Conference 2025 organized by Pharmacy, while also delivering specialized training programs for more than 100 pharmacists of Pharmacy in Ho Chi Minh City, contributing to enhanced professional capabilities and strengthening strategic collaboration with the pharmacy chain system.

Research and Development (R&D)

With R&D investment accounting for approximately 5% of revenue, Imexpharm continues to develop high-technology pharmaceutical products that meet stringent quality standards.

In 2025, the Company maintained 157 ongoing R&D projects, including 66 new projects that were evaluated and planned for feasibility studies, and 91 projects currently in the research and development phase. During the year, Imexpharm also launched 25 new products, exceeding the annual plan of 16 SKUs, demonstrating the Company's strong capabilities in product development and commercialization.

In the fourth quarter, the Company officially launched IMECEP (Ceftazidime/Avibactam 2.5g) – Vietnam's first EU-GMP first generic antibiotic, enhancing patient access to high-quality medicines at affordable costs. At the same time, the Company continued to expand

33
CP
AM
RM
THA



its first-generic portfolio with Cefotetan 1g and 2g, which were granted marketing authorization in 2025 and are expected to be launched in 2026.

In addition to developing new active pharmaceutical ingredients (API), Imexpharm also successfully researched and obtained approval for new dosage forms, including multi-dose powder formulations for Imefed at IMP2 and lyophilized powder for injection or inhalation solution for Colistin IMP 1 MIU at IMP4. These developments help reduce product toxicity, diversify treatment options, and further enhance the Company's manufacturing technology capabilities.

Drug registration

In 2025, Imexpharm obtained 17 new registrations, including 14 drug registrations in Vietnam, two health supplement registrations, and one Marketing Authorization (MA) in Myanmar. This result increased the Company's total number of Marketing Authorizations (MAs) to 429, further affirming its capability in new product development.

Alongside expanding its product portfolio, the Company completed the digital transformation of its entire drug registration process in 2025, covering all stages from document preparation and dossier compilation to digital approval, fully replacing the previously manual processing method.

The digitalization initiative eliminated several manual steps such as document printing, physical approval procedures, and scanning documents for submission to the Drug Administration of Vietnam's public service portal. As a result, the Company achieved savings in time, cost, and resources, while shortening preparation time, accelerating processing speed, and improving productivity. These improvements provide a solid foundation for expediting product registrations and supporting the Company's product portfolio expansion strategy.

Digital transformation

In 2025, Imexpharm recorded a significant advancement in corporate governance and operational management through increased investment in digital technologies. During the year, the Company's IT department simultaneously implemented 10 key technology projects, generating wide-ranging impacts across most of the Company's manufacturing, business, and operational activities.

In upgrading and developing its core application platforms, Imexpharm successfully completed the upgrade to SAP S/4HANA, synchronized data with the Data Warehouse, and restructured its management reporting system, thereby improving data quality and strengthening decision-making capabilities. The CoreSource CRM system was upgraded and integrated with Zalo OA - ZNS, enhancing customer engagement, while DMS tools were expanded to include visit management functions and a Mini App for receivables.

reporting, helping optimize distribution channel management and improve accounts receivable control.

At the same time, the Company standardized and digitalized internal processes on the BASE platform, converting workflows from BASE Request to BASE Service and developing additional digital processes. These initiatives improved process transparency and shortened processing time. The iHRP human resource management system was also comprehensively implemented, covering time attendance, payroll, KPIs, recruitment, and training, together with a mobile application, modernizing HR management and enhancing the employee experience.

In the fourth quarter of 2025, the Company launched Imexpharm Connects, a digital platform and ecosystem designed to strengthen engagement, information transparency, and value sharing with the pharmacist and pharmacy community. This initiative marked an important milestone in the Company's strategy to develop a digital ecosystem and foster sustainable partnerships.

Global business development

Alongside new product development, the Company continued to maintain and hold 28 Marketing Authorizations in the European Union (EU-MAs) covering 11 products, providing a competitive advantage when entering highly regulated markets.

In 2025, Imexpharm recorded positive progress in its global market expansion strategy, submitting one new drug registration dossier in the EU and three dossiers in ASEAN markets (Myanmar, Malaysia, and Singapore). During the year, the Company also successfully signed a distribution agreement for injectable products in Thailand and entered into a Memorandum of Understanding (MoU) with a European partner.

As a result, Imexpharm further expanded its access to markets including the European Union, the United Kingdom, Canada, Switzerland, and Israel, bringing the Company's international presence to more than 40 countries and territories, thereby reinforcing its sustainable growth strategy and deepening its integration into the global pharmaceutical value chain.

III. Financial performance

1. Asset structure

In 2025, Imexpharm's total assets reached VND 2,782.6 billion, an increase of VND 278.1 billion compared with 2024, equivalent to 11.1% growth.

As of 31 December 2025, current assets amounted to VND 1,507.4 billion, increasing by VND 97.9 billion, or 6.9% year-on-year. Liquidity improved as cash and cash equivalents reached VND 189.2 billion, up 16.8%, while short-term financial investments totaled VND 212.1 billion, increasing by 49.4%. Inventories stood at VND 677.7 billion, representing a

14
CÔ
DU
IME
TINH



3.9% decrease, resulting in the inventory ratio declining from 28.2% to 24.4%, reflecting improved inventory management efficiency and more efficient use of working capital.

Non-current assets totaled VND 1,275.2 billion, representing a 16.4% increase year-on-year. The growth was mainly driven by other non-current assets, which reached VND 388.8 billion, up 214.3%, primarily comprising long-term prepaid expenses related to product marketing authorizations, SAP system upgrades, as well as payments for land and building leases and trademark usage rights. Meanwhile, fixed assets amounted to VND 781.0 billion, decreasing VND 77.8 billion, or 9.1%, consistent with the Company's depreciation cycle.

2. Capital structure

In 2025, Imexpharm's equity reached VND 2,306.5 billion, an increase of VND 123.4 billion compared with 2024, equivalent to 5.7% growth, and continued to represent the primary source of funding in the Company's financial structure. Charter capital remained unchanged at VND 1,540.4 billion, while the increase in equity was mainly driven by accumulated retained earnings. During 2025, The Company did not conduct any capital increase during 2025.

As of 31 December 2025, retained earnings amounted to VND 449.0 billion, an increase of VND 128.2 billion compared with 2024. With its current equity structure, Imexpharm continues to maintain a strong capital foundation, prioritizing internal capital accumulation while ensuring financial autonomy to support the Company's medium- and long-term growth plans.

3. Key financial indicators

Indicators	Unit	2024	2025
Liquidity Ratios			
Current Ratio	Times	4.4	4.0
Quick Ratio	Times	2.2	2.2
Capital Structure Ratios			
Debt-to-Total Assets Ratio	%	12.8	17.1
Debt-to-Equity Ratio	%	14.7	20.6
Efficiency Ratios			
Inventory Turnover	Times	1.9	2.1
Total Asset Turnover	Times	0.9	0.9
Profitability Ratios			
Return on Sales (ROS)	%	14.6	14.3
Return on Equity (ROE)	%	15.0	15.6
Return on Assets (ROA)	%	13.1	13.2



- **Liquidity ratios**

In 2025, the current ratio decreased from 4.4 to 4.0 as part of the Company's efforts to optimize capital utilization, while the quick ratio remained stable at 2.2. The Company's liquidity continued to be maintained at a very safe level, ensuring strong liquidity and stable business operations.

- **Capital structure ratios**

Financial leverage indicators increased as the debt-to-total assets ratio rose from 12.8% to 17.1%, while the debt-to-equity ratio increased from 14.7% to 20.6%. The Company proactively utilized additional borrowings to finance investment activities, particularly the Cat Khanh Pharmaceutical Factory Complex Project. Despite this increase, the Company's leverage ratio remains relatively low compared with the industry average, reflecting a solid equity base and a prudent financial management policy. The capital structure continues to be managed prudently, providing a flexible foundation for the Company to respond to potential interest rate fluctuations in the coming period.

- **Efficiency ratios**

The total asset turnover ratio remained stable at 0.9, while inventory turnover improved from 1.9 to 2.1 times, indicating faster inventory circulation and reduced capital lock-up. This reflects improved working capital management efficiency.

- **Profitability ratios**

In 2025, Return on Sales (ROS) slightly declined from 14.6% to 14.3%, mainly due to cost pressures during the period when the Company accelerated investments in sales systems, management infrastructure, and digital transformation initiatives. However, Return on Assets (ROA) increased slightly from 13.1% to 13.2%, while Return on Equity (ROE) improved from 15.0% to 15.6%, indicating continued efficiency in the utilization of both assets and equity. The fact that ROE grew faster than ROA suggests improved equity efficiency, supported by the Company's prudent use of financial leverage, while also reflecting effective cost control and capital structure optimization.

4. Impact of exchange rate and interest rate fluctuations

Unit: VND billion

Indicators	2024	2025	% Change
Interest income	7.9	16.1	104.7%
Interest expenses	3.5	3.2	-9.5%
Foreign exchange gains	3.6	2.9	-19.8%
Foreign exchange losses	1.2	1.2	-3.3%

In 2025, interest income from deposits increased significantly from VND 7.9 billion to VND 16.1 billion, representing a 104.7% increase, as the Company maintained a higher level



of idle cash and optimized cash utilization through term deposits. Interest expenses declined from VND 3.5 billion to VND 3.2 billion, equivalent to a 9.5% decrease, despite the expansion in the scale of operations. Meanwhile, foreign exchange gains decreased from VND 3.6 billion to VND 2.9 billion, representing a 19.8% decline, while foreign exchange losses remained broadly stable at VND 1.2 billion. This stability reflects the Company's prudent foreign exchange risk management policy, which helps mitigate the adverse impact of exchange rate fluctuations on business performance.

IV. Investment status and project implementation

In October 2024, the General Meeting of Shareholders of Imexpharm approved the implementation of the Cat Khanh Pharmaceutical Factory Complex Project. Detailed information about the project is presented as follows:

Project name	Cat Khanh Pharmaceutical Factory Complex
Project objectives	<ul style="list-style-type: none"> · Diversify the product portfolio to better meet growing domestic demand · Increase the Company's revenue and profitability · Support the expansion of export markets
Total land area	97,602.1 m ²
Project operating term	50 years from the date of issuance of the Investment Registration Certificate
Planned project scale	Area: 25,000 m ² Planned design capacity: 1.4 billion product units
Manufacturing standard	EU-GMP
Project location	Quang Khanh Industrial Complex (Phase 1), located in My Tra Commune, Cao Lanh City, and An Binh Commune, Cao Lanh District, Dong Thap Province
Total investment	VND 1,495 billion (One trillion four hundred ninety-five billion Vietnamese Dong)
Planned funding	<ul style="list-style-type: none"> · Equity: 20% – VND 300 billion · Borrowings: 80% – VND 1,195 billion
Estimated project timeline	<ul style="list-style-type: none"> · Construction commencement: Q4 2025 · Construction completion: End of 2028 · Commercial operation: 2028–2030

In 2025, Imexpharm completed all key legal procedures for the Cat Khanh Pharmaceutical Factory Complex Project, including obtaining the Investment Registration Certificate, establishing the Cat Khanh Branch, and officially commencing Phase 1 of the project.

V. Environmental and social responsibility report

1. Environmental performance assessment



In 2025, Imexpharm continued to maintain effective environmental governance, focusing on regulatory compliance, risk control, and improved resource efficiency, in line with the characteristics of pharmaceutical manufacturing and the increasingly stringent standards of the market.

Specifically, the Company further optimized energy consumption through technical solutions and improvement initiatives, achieving total energy savings of 42,600 kWh per year, while generating 48,946 kWh of solar power to reduce reliance on grid electricity. Waste, emissions, and wastewater management were conducted in full compliance with environmental regulations, with no environmental violations recorded during the year. In addition, the implementation of Extended Producer Responsibility (EPR), with a packaging recycling rate of 15%, demonstrates the Company's efforts to manage the product life cycle within the regulatory framework applicable to the pharmaceutical industry.

The Executive Management noted that the absence of any major environmental incidents, together with the continued operation of periodic monitoring and supervision systems, provides a solid foundation for the Company to further implement emission reduction initiatives and enhance environmental performance in the medium and long term.


2. Assessment related to employees

The Executive Management recognizes employees as the core resource determining Imexpharm's competitiveness and sustainable growth. In 2025, the Company maintained a stable, professional, and attractive working environment, reflected in its continued recognition as No.1 in the Pharmaceutical / Medical Devices / Healthcare industry and Top 21 among all companies in Vietnam according to the Anphabe Employer Brand survey, with a preference rate 17 times higher than the market average.

The Company proactively recruited and trained employees to meet operational and business requirements, while continuing to refine and restructure its organizational structure in line with its development strategy and the ongoing administrative restructuring of provincial boundaries. The workforce size was maintained at an appropriate level of 1,456 employees, with a younger workforce structure (Gen Z accounting for 26.6%). The employee turnover rate in 2025 was 13.81%, lower than the previous year (14.64%) and below the market average (approximately 18%), indicating significant improvements in employee retention initiatives.

At the same time, Imexpharm ensured the timely and full implementation of compensation, bonus, and employee welfare policies, including 13th-month salary bonuses, special occasion bonuses, the ESOP program, and other employee benefits, contributing to stronger employee engagement and workforce stability.

Regarding occupational health and safety, the Company conducted periodic health check-ups for 100% of employees (with a total cost of over VND 1.4 billion) and delivered occupational safety training averaging 16.11 hours per production employee. The



Executive Management will continue strengthening safety control measures and training programs in the coming period, aiming to maintain a safe and sustainable working environment.

3. Assessment of the Company's responsibilities to local communities

Imexpharm's community responsibility initiatives in 2025 were implemented with a focused approach, aligned with practical needs and aimed at creating long-term social value. During the year, the Company allocated VND 750 million to social welfare programs, focusing on healthcare, education, support for disadvantaged communities and children, and disaster relief, particularly in localities where the Company operates.

In addition, Imexpharm continued to fulfill its financial obligations to the State, with total tax contributions to the state budget reaching VND 258.5 billion, representing a 21% increase compared with 2024, thereby demonstrating the Company's active role in contributing to socio-economic development.

Community initiatives, together with recognitions such as the Saigon Times CSR – Corporate Social Responsibility Award 2025 and the Top 50 Vietnam Sustainable Enterprises (CSA 2025), have further strengthened the Company's reputation and trust among communities and stakeholders, providing a solid foundation for Imexpharm's stable and sustainable long-term development.

VI. Improvements in organizational structure, policies, and management, key achievements, difficulties and challenges in 2025

1. Improvements in organizational structure, policies, and management

- The Company implemented the consolidation of management positions within the Production, QA, and QC departments at the EU-GMP manufacturing plants in Binh Duong (IMP3 and IMP4, which are geographically adjacent). This initiative aims to streamline the organizational structure, enhance operational alignment, and improve management efficiency.
- The organizational structure and sales branch network were also adjusted to align with the administrative boundary changes implemented by the Government effective from 1 July 2025, ensuring continued operational flexibility and efficiency.
- In addition, the Company restructured and streamlined reporting lines within the supply chain, enhancing transparency, shortening coordination processes, and improving overall operational effectiveness.
- The KPI system was further reviewed and refined to ensure closer alignment with the Company's strategic development objectives, thereby strengthening the linkage and consistency between corporate strategy, departmental targets, and individual performance indicators.

2. Key achievements in 2025



The year 2025 marked significant progress in corporate governance, operational efficiency, and sustainable development at Imexpharm.

- A record three consecutive years maintaining the No.1 position in antibiotic manufacturing and distribution
- A fourth consecutive year achieving double-digit growth in revenue and profit before tax
- First launch in Vietnam of a “first generic” product meeting EU-GMP standards, while continuing to maintain 12/12 production lines certified with EU-GMP.
- Effective cost control, with labor productivity increasing by 14.9% compared with 2024, supporting operational efficiency and sustainable growth.
- Expansion of diverse marketing initiatives across both OTC and ETC channels, demonstrating flexible adaptation to the evolving business landscape in 2025 (including new product launches, electronic invoice regulations, tax policy updates, ETC partnerships, ImexForum, and scientific seminars).
- Continued advancement in digital transformation through the implementation and enhancement of SAP S/4HANA, Base, iHRP, DMS, and Power BI systems.
- Maintained stable employment while continuing to enhance compensation, bonus, and employee welfare policies, with average employee income increasing by 12.1% compared with the previous year despite ongoing market challenges.

3. Difficulties and challenges in 2025


- Rising cost pressures, particularly related to maintaining EU-GMP standards, investing in technology and digital transformation, and meeting increasingly stringent regulatory compliance requirements in export markets.
- A rapidly evolving and complex international regulatory environment, requiring the Company to continuously update technical dossiers, adjust operational processes, and strengthen compliance capabilities.
- In the human resources area, competition for high-quality talent has intensified, particularly for specialized professionals and technical personnel at high-standard manufacturing facilities.
- Uncertainties in the global macroeconomic and geopolitical environment, as well as global market fluctuations, continued to exert pressure on supply chains, logistics costs, and market expansion plans.

VII. Explanation regarding the auditor’s opinion

The independent auditor issued an unqualified opinion on Imexpharm’s audited financial statements for 2025. Accordingly, the Executive Management has no additional explanations to provide.

VIII. Business plan and key priorities for 2026

Entering 2026, Imexpharm’s Executive Management identifies its operational focus as selective growth, improvement of revenue quality, and strengthening a sustainable



operational foundation, rather than expanding purely in scale. The strategy is built upon three key pillars: value-driven growth – efficiency optimization – system standardization.

1. **Revenue growth and sales channel structure:** The Company will shift from expansion based primarily on distribution coverage toward enhancing distribution channel quality and customer value.
 - Restructure the OTC channel in accordance with new tax regulations, prioritizing official pharmacies and modern retail chains, with a focus on customers demonstrating strong compliance capabilities.
 - Strengthen digital marketing initiatives and enhance brand recognition across different product segments.
 - Continue to develop the ETC channel across tender segments, public hospitals, and private healthcare institutions, supported by a broader product portfolio with differentiated dosage forms to optimize cost competitiveness.
 - Selectively invest in the non-prescription (non-Rx) product segment, focusing on products and segments with strong profit margins to balance growth and profitability.
2. **Expansion of international business:** Imexpharm will continue transforming its EU-GMP manufacturing capabilities into tangible export revenue growth.
 - Implement key updates to EU Marketing Authorization (EU-MA) dossiers, including shelf-life extensions, batch size increases, and the addition of CEP-compliant API sources.
 - Submit additional drug registration dossiers in the EU.
 - Proactively evaluate and select potential products for collaboration with international partners, gradually increasing the proportion of export revenue and expanding market coverage.
3. **Strengthening manufacturing capabilities and standardizing quality systems:** The Company will continue reinforcing its EU-GMP manufacturing foundation to support long-term growth.
 - Thoroughly prepare for the WHO-GMP re-inspection (IMP1) and EU-GMP re-certifications (IMP2, IMP3) to ensure operational continuity and system-wide credibility.
 - Implement key improvement initiatives at IMP3 and IMP4 aimed at enhancing productivity and operational safety.
 - Conduct research and evaluation to prepare for a manufacturing automation roadmap, moving toward a modern, low-risk, and cost-optimized production model.
 - Continue evaluating secondary sources for APIs and excipients to enhance supply security and strengthen control over raw material quality.





- Further refine the investment plan for the Cat Khanh Pharmaceutical Factory Complex Project, targeting specialty drugs and biologics in line with the technology transfer roadmap from the new strategic investor,
- 4. R&D and new product development:** The Company will reinforce long-term growth drivers by expanding its high-value product portfolio.
- Target the launch of at least 15 new products, focusing on segments with strong potential for tender participation and export opportunities.
 - Continue expanding the first generic product portfolio, particularly in essential medicines and specialty drugs, to strengthen competitive advantages, optimize profit margins, and enhance the Company's position in both domestic and international markets.
 - Expand bioequivalence (BE) research and publication activities to strengthen scientific credibility and improve product competitiveness.
- 5. Digital transformation and ESG integration:** The Company will accelerate digitalization and ESG integration across operations to support sustainable development.
- The iHRP system will be further refined and officially implemented in 2026, becoming a core human resource management platform to enhance performance transparency, resource optimization, and workforce development in line with regional enterprise standards.
 - Imexpharm Connects will be developed into a central digital platform for marketing and market engagement, enabling personalized interactions with pharmacies, physicians, and partners, thereby improving sales investment efficiency.
 - ESG principles will continue to be integrated into operations, from information transparency, investor relations, and fair human resource management to resource optimization and waste reduction.

ON THE BEHALF OF
EXECUTIVE BOARD
GENERAL DIRECTOR



PHARMACIST. TRAN THI DAO



IMEXPHARM CORPORATION**SOCIALIST REPUBLIC OF VIETNAM**
Independence - Freedom - Happiness

No.: 03 /BC-HĐQT-IMP

Dong Thap, March 25, 2026

**REPORT OF THE AUDIT COMMITTEE
AND THE INDEPENDENT MEMBER OF THE BOARD OF DIRECTORS
MR. HOANG DUC HUNG****I. Functions, duties and independence of the Audit Committee**

The Audit Committee (the "AC") is a specialized committee under the Board of Directors ("BOD"), operating in accordance with its approved Charter, with the function of assisting the BOD in supervising the truthfulness and fairness of the financial statements, the effectiveness of the internal control system, risk management and the Company's compliance with laws.

The AC reviews related-party transactions, oversees internal audit activities, and assesses the independence, objectivity and quality of the external audit. The Committee is entitled to full access to relevant information and documents and to work directly with the Executive Board, the internal audit function and the independent audit firm in order to perform its oversight function. The independence of the AC is ensured through its composition of non-executive BOD members, in which the independent member plays a key role and no conflict of interest arises. In accordance with laws and good corporate governance practices, the AC contributes to enhancing transparency, strengthening shareholder confidence and ensuring an effective and sustainable corporate governance foundation for the Company.

II. Composition and activities of the AC in 2025**1. Members of the AC**

No.	Full name	Position on the BOD	Position on the AC	Appointment date
1	Hoang Duc Hung	Independent member of the BOD	Chairman	23 Feb 2024





2	Truong Minh Hung	Non-executive member of the BOD	Member	23 May 2024
---	------------------	---------------------------------	--------	-------------

The AC of Imexpharm comprises 02 members, in which the Chairman of the AC is an independent member of the BOD.

In 2025, there was no change in the membership of the AC.

2. Activities of the AC in 2025

In 2025, the AC fully performed its oversight activities over finance, internal control and risk management within its delegated authority, specifically as follows:

- The AC supervised and discussed the audited financial statements for 2024, the reviewed semi-annual financial statements for 2025, and the quarterly financial statements for 2025 before they were submitted to the BOD for consideration.
- The AC assessed the effectiveness of the operation of the internal control system, coordinated with the Executive Board to update the Company-level key risk register for 2025, reviewed related-party transactions and oversaw internal audit activities. On that basis, the AC monitored compliance with information disclosure requirements, legal regulations and requirements of regulatory authorities.
- In 2025, the AC held 02 official meetings to discuss key matters, including:
 - (1) Discussion on the audited financial statements for 2024 and the reviewed interim 6-month financial statements for 2025.
 - (2) Discussion on the structure of the Internal Audit function, including its operating functions and the proposal to strengthen resources.
 - (3) Discussion and proposal on a number of emerging risks to be added to the Company-level key risk register for 2025, including:
 - Considering the impacts of any changes of major shareholders (if any) on the Company, and supervising compliance with information disclosure related to changes of major shareholders.
 - Challenges in cash flow management and compliance of the new large-scale project - Cat Khanh Pharmaceutical Plant Complex.
 - Updating and complying with continuous changes in legal regulations for the pharmaceutical and healthcare sector in 2025.
- In addition, the Chairman of the AC also supported the BOD with advisory opinions on corporate governance and on environmental – social – governance (ESG) policies, thereby contributing to raising Imexpharm's operating standards.





- The AC also supported the BOD in reviewing and proposing the appointment of KPMG as the independent audit firm, based on criteria ensuring quality and independence in auditing the Company's financial statements.

Accordingly, the AC has diligently performed its oversight duties and provided timely recommendations to help Imexpharm improve governance efficiency, strengthen risk control and achieve sustainable development.

III. Oversight results of the AC over business operations and financial position in 2025

1. Corporate governance, the BOD and the Executive Board

In 2025, the AC supervised the activities of the Company, the BOD and the Executive Board to ensure compliance with laws, the Company's Charter and internal corporate governance regulations. For issues with potential compliance risks, the AC promptly discussed with the Executive Board and reported to the BOD for direction, while making recommendations to strengthen risk management and internal control.

The AC supervised the implementation of resolutions of the General Meeting of Shareholders ("GMS") and the BOD, monitored decisions related to development strategy and expansion investments, and assessed their alignment with the Company's business objectives in order to make recommendations.

For the Executive Board and management levels, the AC maintained mechanisms for information exchange and periodic reporting to monitor the implementation of business plans, financial and accounting control, information disclosure and compliance with internal procedures; thereby supporting the BOD and the Executive Board in enhancing governance effectiveness and mitigating key risks.

2. Financial statements

The AC was updated on a timely basis and provided feedback on the process of preparation, review and audit of the quarterly, semi-annual and annual financial statements for 2025 prior to their publication. Through professional discussions and updates from the independent auditor, the AC reviewed the basis on which the financial statements were prepared in compliance with prevailing accounting standards, and which present a true and fair view of the Company's financial position, operating results and cash flows, without material misstatements or indications of fraud that could affect the quality of the information. The Company fulfilled its financial reporting disclosure obligations, thereby enhancing transparency and strengthening the confidence of shareholders and investors.

3. Internal control system and risk management

In 2025, the Company continued to improve its risk management (RM) and internal control framework in line with advanced practices. The Company maintained the Risk Management and Compliance Department to support the Executive Board in implementing RM in accordance with good practices. This function coordinated with business units/departments to perform risk self-assessment, develop policies, procedures and the approved RM





Manual; and updated the annual key risk register, thereby improving the quality of control measures in operations.

During the year, the Company conducted training programs on risk and compliance, particularly at sales branches, in order to unify awareness across the system and prevent frauds and violations. The AC assessed that RM and Compliance activities were implemented seriously by the BOD and the Executive Board, contributing to ensuring safe and stable business operations for the Company.

4. Internal audit and independent audit

The AC also supervised the plan to establish and implement the internal audit ("IA") function in order to meet current legal requirements, and discussed and proposed to the BOD and the Executive Board possible options for performing IA activities using internal resources or outsourcing.

With respect to the independent audit, the AC communicated with the audit firm to ensure the independence, objectivity and quality of the audit report. Feedback from the independent auditor indicated that, during the year, there were no changes in accounting estimates or material error corrections that needed to be highlighted.

In addition, the AC monitored and urged compliance with laws in the areas of finance – accounting, tax, environment, pharmaceutical business and corporate governance, and did not record any non-compliance with the above-mentioned regulations based on reports of the Executive Board and functional departments.

IV. Remuneration of AC members and related-party transactions

1. Remuneration of AC members

The remuneration and bonuses of each AC member in 2025 are presented in detail in the audited financial statements for 2025, Note 34 – Notes to the financial statements.

In addition to the annual remuneration and bonus scheme approved each year, AC members are covered under the Company's directors and officers (D&O) liability insurance. Furthermore, the Company directly pays business travel expenses such as air tickets and accommodation when they perform tasks as required by their duties.


2. Related-party transactions

In accordance with regulations, during the year the AC instructed the review and close supervision of transactions between the Company and related parties, including approval, recognition and information disclosure.

V. Hoạt động mua bán và sáp nhập

At the beginning of 2026, the BOD was informed of and received the public tender offer dossier for IMP shares from LIAN SGP HOLDING PTE. LTD., specifically as follows:

- Total number of shares registered for the tender offer: 120,059,970 shares, equivalent to 77.94% of the charter capital of Imexpharm Corporation, and equivalent to 77.96%



3844
TY C
PHÁ
HAI
ING T



of the total voting shares of Imexpharm Corporation.

- Tender offer price: VND 57,400 per share;
- Securities company acting as tender offer agent: SSI Securities Corporation - Hanoi Branch.

The AC provided professional opinions to the BOD for consideration in the process of formulating recommendations and performing the obligations of the target company's BOD in relation to the tender offer in accordance with prevailing laws (Article 87 of Decree No. 155/2020/ND-CP guiding the Law on Securities), specifically as follows:

- The positive impacts and advantages for Imexpharm's business operations when a new investor being LIAN (and its group entities) participates as a major name in the pharmaceutical industry with new technologies, advanced management processes and a competitive supply network, etc.
- Scenarios and risks that Imexpharm may face in not meeting the minimum shareholding ratio requirements for minority shareholders of a company listed on HSX. Therefore, there is a need for effective mechanisms to supervise and manage timely information exchange to ensure fairness and protect the interests of all shareholders, including minority shareholders.
- Mechanisms to identify, manage transparently and disclose related party transactions when LIAN and its group entities participate, in accordance with domestic legal regulations, including in cases where such transactions are beneficial to Imexpharm.

VI. Assessment of the 2025 management performance by the independent BOD member

– Mr. Hoang Duc Hung

- Mr. Hoang Duc Hung highly appreciates the management capability of the Executive Board in 2025, as evidenced by the maintenance of stable growth outperforming the industry average in a highly competitive pharmaceutical market. Net revenue reached VND 2,441 billion, up 10.7% year-on-year, and profit before tax reached VND 446 billion, up 10.4%, as a result of management policies focusing on a high-value product portfolio, operational optimization and cost control.
- In addition to the financial results, Mr. Hoang Duc Hung acknowledges the efforts of the Executive Board in enhancing transparency, compliance and risk management. Maintaining standard practices in reporting, providing sufficient and timely information to the BOD, together with close coordination in implementing resolutions and supervising the key investment project – Cat Khanh Pharmaceutical Plant Complex, have contributed to strengthening shareholder and investor confidence in the Executive Board's management capability





VII. Work plan and proposals of the AC for 2026

To align with the Company's development strategy and objectives for 2026, the AC will focus on the following key activities:

1. Change of major shareholders and expansion of investments

The AC will continue to strengthen its oversight role in the context of the Company implementing new growth plans, changing major shareholders and expanding investments in the key project – Cat Khanh Pharmaceutical Plant Complex.

The AC proposes that the Company continue to review the Company-level risk register for 2026 in relation to:

- (1) Changes in senior personnel (if any) during the process of changing major shareholders;
- (2) Changes in strategy, business model and emergence of related-party transactions, etc. (if any) after the change of major shareholders;
- (3) Implementation of the investment plan at the Cat Khanh Project.

In addition, it is also necessary to pay attention to the timely update and communication of the Company's shareholder structure to ensure compliance with the requirements applicable to public companies.

2. Oversight of financial reporting and information disclosure

The AC will continue to direct and oversee the quality of financial reporting, ensuring transparency, timeliness and full compliance with the changes in accounting standards in 2026 under Circular No. 99/2025/TT-BTC effective from 01 January 2026, as a transitional step to bring VAS closer to basic IFRS for Vietnam's 2026–2030 roadmap.

At the same time, the AC will continue to supervise the Company's information disclosure activities on the stock market, as well as compliance with legal regulations and requirements of regulatory authorities related to the securities market.

3. Oversight of independent audit and internal audit


The AC will continue to monitor and assess the independence and effectiveness of the independent audit and of internal audit activities; supervise the development and implementation of risk-based audit plans, as well as the implementation of post-audit recommendations.

The AC also proposes considering the supplementation of human resources in charge of the Internal Audit function in order to ensure its independence and effectiveness.

4. Training and enhancement of compliance awareness

The AC highly appreciates, acknowledges and proposes that the Company continue to strengthen training activities on risk management, compliance and internal control for management and departments/divisions in 2026, in order to promptly update a wide range of newly issued legal regulations related to the pharmaceutical sector and other activities of

03844
G TY
C PH
PHAI
NG T





the Company, thereby enhancing awareness of operational safety, compliance, responsibility and consistency throughout the system.

The AC also proposes that the BOD promulgate a Whistleblowing Regulation (regulation on reporting violations) in 2026, based on recommendations from internal audit activities.

5. Oversight of related-party transactions

The AC also proposes that the BOD soon promulgate a separate Regulation on Supervision of Related-Party Transactions, in order to establish mechanisms for timely identification and approval within proper authority, as well as full and timely information disclosure, in strict compliance with corporate governance regulations.

**REPRESENTATIVE OF THE AUDIT COMMITTEE
CHAIRMAN OF THE AC**

HOANG DUC HUNG



IMEXPHARM CORPORATION

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness



No: 04 /BC-HĐQT-IMP

Dong Thap, March 25, 2026

**REPORT ON PERFORMANCE ASSESSMENT OF
INDEPENDENT MEMBER OF THE BOARD OF DIRECTORS**

MR. CHUNG SUYONG

To: The 2026 Annual General Meeting of Shareholders

In my capacity as an Independent Member of the Board of Directors of Imexpharm Corporation (hereinafter referred to as "Imexpharm" or the "Company") for the 2023–2027 term, I have, during my tenure, complied with the Law on Enterprises of Vietnam, the Law on Securities of Vietnam, as well as the Company's Charter and other relevant regulations. I have devoted myself to performing my duties diligently and responsibly, fully promoting the role of an independent member of the Board of Directors in the governance of a listed company.

In 2025, I actively attended relevant meetings, carefully reviewed the submissions and reports presented at meetings of the Board of Directors (the "BOD"); closely monitored regulations relating to listed companies in Vietnam; faithfully fulfilled my obligations as an independent BOD member; made reasonable recommendations on material matters of the Company; and protected the legitimate rights and interests of the Company and its shareholders, particularly minority shareholders.

Since joining the BOD of Imexpharm in April 2023 as an independent BOD member, I have facilitated connections between Imexpharm and international partners, while providing in-depth advice on business strategy in the pharmaceutical industry in both the Vietnamese and international markets.

I hereby report on my activities in 2025 as follows:

I. Assessment by the Independent member on the BOD's activities

In 2025, in my role as an independent member, I assess the performance of the BOD as follows:

- 1. Compliance:** The BOD operated in accordance with the provisions of the Law on Enterprises, the Law on Securities, the Company's Charter, the Internal Corporate Governance Regulations, and the Regulations on Operation of the Board of Directors of Imexpharm.
- 2. Transparency:** Discussions at meetings were conducted in a straightforward and candid manner. The Management provided timely and sufficient information, enabling me to exercise oversight, make recommendations, and cast votes appropriately.
- 3. Protection of shareholders:** The BOD prioritized consideration of the impact of major decisions on minority shareholders, particularly in matters relating to dividend distribution and additional share issuances.



II. Detailed activities in 2025:

1. Attendance at meetings, voting and share ownership

- Participation in governance: I attended all 10/10 BOD meetings held in 2025, achieving an attendance rate of 100%.
- Voting position: I voted in favor of all 11 resolutions and decisions issued by the BOD in 2025
- Share ownership: As at the end of 2025, I did not hold any IMP shares.

2. Oversight of related party transactions

According to discussions with the Audit Committee, the Company's related-party transactions during the year were reviewed and assessed as normal commercial transactions conducted at fair and reasonable prices, following lawful procedures and with full information disclosure, without causing any detriment to the interests of the Company and its shareholders.

3. Mergers and acquisitions activities

- At the beginning of 2026, the Company's BOD received a public tender offer dossier for IMP shares from Lian SGP Holding PTE. LTD. The BOD convened a meeting and held discussions to reach its opinions and recommendations regarding Lian SGP's public tender offer, and fully carried out information disclosure in accordance with the provisions of Decree No. 155/2020/ND-CP guiding the implementation of the Law on Securities, in its capacity as the target company. I believe that the participation of Livzon Pharmaceutical Group Inc. has the potential to support product development and Imexpharm's key projects in the coming period.
- During the year, the BOD also approved an additional investment of VND 30.1 billion to maintain its shareholding ratio in the associate company Agimexpharm (AGP), with a view to providing capital to develop EU-GMP standard factories, thereby enabling AGP to compete in a higher market segment.

4. Disclosure of financial information and audit reports

The Company complied with the information disclosure regulations of the Vietnam Stock Exchange and the Listing Rules of the Ho Chi Minh City Stock Exchange. The Company disclosed quarterly financial statements, reviewed semi-annual financial statements, audited annual financial statements, and the Annual report within the statutory deadlines. The disclosed information contained no material misstatements, was not misleading, and did not omit important information. The Management is committed to the truthfulness, fairness, accuracy, and completeness of the disclosed information.

5. Appointment or dismissal of the audit firm

- Pursuant to the authority approved and delegated by the 2025 Annual General Meeting of Shareholders (the "AGM"), the BOD organized a meeting to seek opinions from its members and officially appointed KPMG Limited (Vietnam) as the independent audit firm for the 2025 financial year, based on the recommendation of the General Director and the Audit Committee.
- The appointment of KPMG Vietnam as the independent audit firm for the second consecutive year was based on key foundations, including suitability, independence, and transparency. The selection process was conducted in the proper sequence, ensuring legality and compliance with the Company's Charter.



40038
ÔNG T
ƯỚC P
IMEXPH
H ĐỒN



6. Changes in accounting policies, accounting estimates, or adjustments of material errors

According to discussions with the Company's Chief Accountant and the independent auditor, during the year the Company did not make any changes to its accounting policies or accounting estimates, and no adjustments for material errors arose.

7. Nomination, appointment, or dismissal of members of the BOD and the Executive Board

During the year, the BOD approved the dismissal of one Deputy General Director in charge of Finance. The selection of a successor is being carried out in a prudent manner to ensure continuity and stability in the Company's financial management. I highly appreciate the Executive Board members who have assumed and concurrently undertaken the Finance - Accounting function, ensuring smooth and efficient operations during the interim period pending the appointment of a successor.

In 2025, the Company did not appoint any new senior executives. The current leadership team continues to ensure optimal management capability and remains aligned with the strategic objectives approved by the General Meeting of Shareholders.

8. Remuneration and share-based incentive programs

- The remuneration and bonus policy for the BOD is implemented in accordance with the approval of the Annual General Meeting of Shareholders and the agreements between the Company and BOD members, based on the recommendations of the Nomination and Compensation Committee
- In 2025, the General Meeting of Shareholders, via written ballot, issued Resolution No. 02/2025/NQ-ĐHĐCĐ-IMP dated 28 October 2025 to approve: (1) the cancellation of the Cash Bonus Program for key personnel for 2026; and (2) the approval of the plan to issue shares under the Employee Stock Ownership Plan (ESOP).

I consider this a necessary step to help Imexpharm preserve its financial resources for key investment activities, while creating strong motivation for key personnel to increase corporate value and optimize benefits for stakeholders.

III. Overall assessment and recommendations

1. Orientation towards ESG practices

From the perspective of an independent BOD member, I assess that in 2025 the Company significantly strengthened its governance foundation towards sustainability and alignment with best practices. ESG practices in accordance with international standards have been established as a guiding principle in strategic management and operations, ensuring growth objectives are associated with the long-term interests of shareholders and other stakeholders.

Overall, governance activities in 2025 demonstrated consistency between strategy, risk management, and sustainable development, thereby creating a solid foundation for the next growth phase.

2. Assessment of business performance in 2025 and recommendations



I acknowledge and highly appreciate the management capability of the Executive Management Board in 2025, particularly its strategic vision in affirming Imexpharm's leading position in the EU-GMP standard pharmaceutical segment and high-tech product lines.

The breakthrough growth in revenue and profit during the year is evidence of a balanced and effective development strategy across both OTC and ETC channels. Among these, the ETC channel continues to be the medium- and long-term growth driver, thanks to the Executive Board's agility in capitalizing on market demand for pharmaceuticals with complex dosage forms. The pioneering launch of "first generic" product lines, coupled with strong R&D capabilities, has created a sustainable competitive advantage, enabling Imexpharm to differentiate itself in the market.

In addition to expanding new therapeutic groups for chronic diseases such as cardiovascular diseases, diabetes, obesity, digestive disorders, etc., I also propose that the Company continue researching and improving diverse and convenient dosage forms, and innovating product packaging designs to create a strong impression and brand recall among customers, as these are also critical factors.

Looking ahead, I expect the Executive Board to continue placing innovation at the core, increasing the technological content of the high-value product portfolio in order to optimise the capacity utilisation of the EU-GMP standard factories, while further expanding cooperation and presence in international markets. Ultimately, maintaining a balance between revenue growth, financial performance and foundational investments, together with enhancing corporate governance, will be the key for Imexpharm to preserve its stable growth momentum and realise its objective of delivering long-term value for shareholders and other stakeholders.

Respectfully yours.

Independent Board Member



Chung Suyong



IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: *03* /TTr-HĐQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re.: Approval of the audited 2025 Financial Statements

Kindly Attn: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises;
- Pursuant to the Charter of Imexpharm Corporation (the “Company”);
- Based on the audited Financial statements prepared by KPMG Limited’s Branch in Ho Chi Minh City (Vietnam) dated March 20, 2026.

The Board of Directors (“BOD”) respectfully submits to the 2026 Annual General Meeting of Shareholders (“AGM”) for approval of the 2025 Financial statements of Imexpharm Corporation which has been audited by KPMG Limited’s Branch in Ho Chi Minh City (Vietnam) as follows:

The audited 2025 financial statements have been disclosed in accordance with regulations on the Company’s website, including:

1. Company’s profile;
2. Statement of the Board of Management;
3. Independent Auditor’s Report;
4. Balance sheet (Form No.B 01 – DN, Issued under Circular No. 200/2014/TT-BTC dated December 22, 2014 by the Ministry of Finance)
5. Income Statement (Form No. B02-DN);
6. Cash Flow Statement (Form No. B03-DN);
7. Notes to the Financial Statements (Form No. B09-DN).

In which:

Some basic indicators in the audited 2025 Financial statements:



No.	Key Targets	Unit	2025	2024
1	Total assets	VND	2,782,634,485,220	2,504,776,666,933
2	Revenue from sales of goods	VND	2,914,294,074,254	2,512,786,046,784
3	Net revenue	VND	2,441,085,482,086	2,205,119,938,413
4	Profit before tax	VND	446,247,738,093	404,192,934,555
5	Profit after tax	VND	349,138,023,396	320,862,393,082

Respectfully submitting to the AGM for consideration and approval.

ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRPERSON



SUNG MIN WOO



IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 04 /TTr-HĐQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re.: Profit distribution for 2025 and dividend plan for 2026

To: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the current Law on Enterprises;
- Pursuant to the Charter of Organization and Operation of Imexpharm Corporation (the "Company");
- Pursuant to the audited financial statements for 2025, prepared by KPMG Limited's Branch in Ho Chi Minh City (Vietnam) dated March 20, 2026.
- Pursuant to Resolution No. 01/2025/NQ-ĐHĐCĐ-IMP of the Annual General Meeting of Shareholders ("AGM") dated April 25, 2025, regarding the dividend payment plan for 2025.

The Board of Directors ("BOD") respectfully submits to the 2026 Annual General Meeting of Shareholders ("AGM") for approval the profit distribution plan for the fiscal year 2025 and the dividend plan for the fiscal year 2026 as follows:

1. Profit distribution plan for 2025

No.	Description	Proportion	Amount (VND)
1	Total profit before tax for 2025		446,247,738,093
2	Total profit after tax for 2025		349,138,023,396
3	(+) Utilization of Development Investment Fund (*)		4,803,003,971
4	(-) Gain from foreign exchange revaluation		(1,884,766)
5	(+) Retained earnings from previous years		95,072,379,977
6	Profit available for distribution	100.00%	449,011,522,578
	Cash dividend payment of 6% of charter capital (**)		
7	(154,008,962 shares × 600 VND/share)	20.58%	92,405,377,200
8	Bonus and welfare fund	10.91%	49,000,000,000
9	Undistributed retained earnings	68.51%	307,606,145,378



(*): In 2025, the Company used the Development Investment Fund to offset the administrative tax penalty in accordance with Decision No. 3013/QĐ-CT dated August 29, 2025 of the Director of the Tax Department (which had been disclosed in accordance with regulations). The aforesaid use of the Development Investment Fund was approved by the General Meeting of Shareholders.

(**): The 2025 Annual General Meeting of Shareholders (AGM) approved a target 2025 cash dividend rate of 5% and authorized the Board of Directors (BOD) to make the final decision. Based on the 2025 business performance, the BOD is proposing a cash dividend of 6%, which is 1% higher than the initial target.

❖ **Dividend for 2025: 6% of Charter Capital in Cash**

The Company pays dividends to shareholders within 30 days after receiving the shareholder list from the Vietnam Securities Depository and Clearing Corporation (VSDC), but no later than 3 months from the conclusion of the 2026 AGM.

2. Dividend plan for 2026

The cash dividend rate for 2026 is expected to be 5%–8% of charter capital, and the Board of Directors shall be authorized to decide the specific rate depending on the Company's 2026 business results.

Respectfully submitting to the AGM for consideration and approval.

ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRPERSON


SUNG MIN WOO

4433-C.T.C.P
Y CP
HÀM
ARM
THÁP



IMEXPHARM CORPORATION

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 05 /TTr-HDQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re: Approval of the 2026 Business Target and Plan

To: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the current Law on Enterprises;
- Pursuant to the Charter on organization and operation of Imexpharm Corporation;
- Pursuant to the Report and assessment of the BOD's performance; and Report on business and financial performance of the Board of Management, key business targets and plan in 2026.

The Board of Directors (BOD) respectfully submits to the Annual General Meeting of Shareholders (AGM) for consideration and approval of the 2026 Business Target and Plan with the following main contents:

I. 2026 Business plan targets


Based on our current capabilities and the 2026 business targets, the BOD proposes the following key performance targets:

No.	Target	Unit	Actual for 2025	Plan 2026	Growth
1	Total Revenue	VND Billion	2.914,3	3.200,0	9,8%
2	Profit before tax	VND Billion	446,2	502,0	12,5%
3	EBITDA	VND Billion	567,2	637,0	12,3%

II. Proposal to the AGM

The BOD respectfully submits this proposal to the AGM for consideration and approval:

1. The 2026 business plan targets as set out in Section I.
2. To authorize the BOD, based on the actual business situation, to adjust the plan (if necessary) and decide on implementation measures to ensure the best interests of the shareholders




Respectfully submitted to the AGM for consideration and approval

ON THE BEHALF OF BOD

CHAIRPERSON


SUNG MIN WOO





IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 05/BC-HĐQT-IMP

Dong Thap, March 25, 2026

REPORT

**Re.: Utilization of the 2025 operating expenses, remuneration, and bonuses
for the Board of Directors and Board Committees**

Kindly Attn: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly on June 17, 2020, and its subsequent amendments and supplements;
- Pursuant to the Charter of Imexpharm Corporation (the “**Company**”).

The Board of Directors (“**BOD**”) respectfully reports to the 2026 Annual General Meeting of Shareholders (“**AGM**”) on the operating expenses, remuneration, and bonuses of the BOD and its Committees for 2025 as follows:

No.	Items	Amount (VND)
1	Unused remuneration, bonuses of the BOD from the previous year	13,553,563,317
2	Remuneration and bonuses accrued in 2025 (2% of profit before tax and expenses of BOD)	9,107,096,696
3	Remuneration, bonus, operating expenses paid in 2025	19,823,807,101
4	The unused remuneration, bonuses transferred to 2026	2,836,852,912

Respectfully report to the AGM.

**ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRPERSON**



SUNG MIN WOO



IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 06 /TTr-HĐQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

**Re.: Operating Expenses of the Board of Directors
and the Board Committees for 2026**

Kindly Attn: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly on June 17, 2020, and its subsequent amendments and supplements;
- Pursuant to the Charter of Imexpharm Corporation (the “**Company**”).

The Board of Directors (“**BOD**”) respectfully reports to the 2026 Annual General Meeting of Shareholders (“**AGM**”) for consideration and approval of the total remuneration and operating expenses for the BOD and the Board Committees for the year 2026 as follows:

1. Remuneration and expenses for the BOD and Board Committees

- The appropriation rate is 2% of Profit Before Tax (PBT), calculated before the deduction of actual expenses incurred for the BOD and the Board Committees.

2. Bonuses for the achievement of profit targets

- Profit-plan completion bonus: The Board of Directors and its Committees shall be awarded a bonus equal to 1% of profit after tax if the Company fulfills its 2026 profit-before-tax plan.
- Bonus on profit exceeding the plan: The BOD and BOD Committees are entitled to a bonus equal to 5% of the portion of profit before tax that exceeds the target.

Respectfully report to the General Meeting of Shareholders for approval.

Best regards.

**ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRPERSON**



SUNG MIN WOO





IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

No.: 07 /TTr-HĐQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re.: Selection of an independent auditor for 2026


To: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly on June 17, 2020, and its subsequent amendments and supplements;
- Pursuant to the Charter of Imexpharm Corporation (the "**Company**");
- Pursuant to the List of Audit Firms and Practicing Auditors approved to provide audit services for public interest entities in the securities sector for the year 2026, issued in conjunction with Decision No. 902/QĐ-UBCK dated November 19, 2025, by the Chairperson of the State Securities Commission

The Board of Directors (the "**BOD**") respectfully submits to the 2026 Annual General Meeting of Shareholders (the "**AGM**") for approval of the principles and proposals for selecting an independent audit firm to perform the review of the Interim Financial Statements and the audit of the 2026 Annual Financial Statements of the Company as follows:

1. Principles and orientations for the selection of an independent auditor

- The audit firm is included in the list of audit firms approved in 2026 to audit listed entities as announced by the State Securities Commission;
- The audit firm has at least 10 auditors each having at least 24 months of practical auditing experience in Vietnam;
- It has a quality control system established in accordance with Vietnamese auditing standards;
- It has obtained professional liability insurance or established a professional risk-reserve fund in accordance with regulations of the Ministry of Finance;
- It has experience in auditing pharmaceutical companies;
- It is a reputable audit firm offering reasonable audit fees;
- It is able to issue audit reports quickly and in a timely manner so as to meet information disclosure requirements and the preparation of reports for the AGM.





2. The demand for selecting an independent auditor for the Financial statements FY 2026

Imexpharm's BOD would like to submit to the AGM for consideration and approval the authorization for the BOD to appoint one (1) of the following four (4) audit firms for the fiscal year 2026:

- KPMG Vietnam Co., Ltd.
- Grant Thornton (Vietnam) Ltd.
- Deloitte Vietnam Co., Ltd.
- Ernst & Young Vietnam Ltd.


Respectfully submitting to the 2026 AGM for consideration and approval.

ON BEHALF OF THE BOD

CHAIRPERSON



SUNG MIN WOO



IMEXPHARM CORPORATION

Số: 08 /TTr-HĐQT-IMP

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Dong Thap, March 25, 2026

PROPOSAL

***Re: Amendment and supplementation of business lines
 Imexpharm Corporation***

To: Esteemed Shareholders of Imexpharm Corporation

Pursuant to:


- Law on Enterprises No. 59/2020/QH14 passed by the National Assembly on June 17, 2020, as amended by Law No. 03/2022/QH15 dated January 11, 2022;
- Law on Pharmacy No. 105/2016/QH13 dated April 06, 2016 of the National Assembly, as amended and supplemented by Law No. 28/2018/QH14 dated June 15, 2018 and Law No. 44/2024/QH15 dated November 21, 2024, which takes effect from July 01, 2025;
- Pursuant to the Prime Minister’s Decision No. 36/2025/QĐ-TTg dated 29 September 2025 on the promulgation of the Vietnam Standard Industrial Classification;
- Charter on organization and operation of Imexpharm Corporation (the “**Company**”).

In order to meet the Company’s business operation needs in the upcoming period, the Board of Directors (the “**BOD**”) respectfully submits to the 2026 Annual General Meeting of Shareholders (the “**AGM**”) for its consideration and approval the adjustment of the scope of operation and the amendment and supplementation of certain business lines of the Company, with details as follows:


1. Amendment and supplementation of the Company’s business lines

The BOD respectfully proposes that certain business lines of the Company be amended and supplemented, with details as follows:

No.	Current business line description	Proposed amendments and supplementations	Remarks
1	4649: Trading household appliances Details: Wholesaling cosmetics (excluding wholesale of goods under the list of goods prohibited for export,	4649: Wholesale of other household goods Details: - Export of drugs and drug materials.	Addition of business lines: Wholesale, import and export of medicines, pharmaceutical raw materials,



No.	Current business line description	Proposed amendments and supplementations	Remarks
	import and distribution by foreign investors, foreign-invested business entities).	<ul style="list-style-type: none"> - Import of drugs and drug materials. - Wholesale of drugs and drug materials manufactured by the Company, contract-manufactured or transferred by technology in Vietnam to medical examination and treatment establishments, vaccination establishments and other medical establishments; drug rehabilitation establishments; state drug and drug-material testing establishments; science and technology organizations and training establishments conducting research and teaching related to pharmacy; pharmaceutical business establishments; and establishments that have been granted an Investment Registration Certificate for drug manufacturing but have not yet been granted a Certificate of eligibility for pharmaceutical business for pilot production and assessment of drug manufacturing processes. - Wholesale of drugs and drug materials imported by the Company to drug and drug-material wholesalers. 	pursuant to Article 53a of Law No. 44/2024/QH15 dated November 21, 2024 amending and supplementing certain articles of the Law on Pharmacy.



No.	Current business line description	Proposed amendments and supplementations	Remarks
		- Wholesale, import and export of cosmetics.	
2	4632: Wholesaling food Details: Wholesaling food, functional foods, drinks, alcoholic and carbonated drinks (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	4632: Wholesale of food Details: Wholesale and <u>import/export</u> of food, functional foods, beverages, alcoholic beverages and carbonated drinks (excluding the wholesale and <u>import/export</u> of goods on the list of goods for which foreign investors and foreign-invested economic organizations are not allowed to exercise the right to export, the right to import and the right to distribute).	To supplement the function of import and export of food
3	4679: Other uncategorized specialized wholesale Details: Wholesaling, importing/exporting medical equipment (excluding video recording products and goods under the list of goods and services on which state monopoly is applied) and medical instruments, chemicals and raw materials, chemicals for the production of functional foods, disinfectants and	4679: Other specialized wholesale not elsewhere classified Details: Wholesale and import/export of medical equipment and instruments, chemicals and raw materials and chemicals for the manufacture of functional foods, and disinfectants and antiseptics for humans (excluding the wholesale of goods on the list of goods for which foreign investors and foreign-invested economic organizations are not allowed to exercise the right to export, the right to import and the right to distribute, <u>and goods and services on the list of</u>	- To revise the wording and add: "(... and goods and services on the list of goods and services subject to state monopoly in commercial activities)"


3844

3 TY


: PH

PHA

ÔNG




No.	Current business line description	Proposed amendments and supplementations	Remarks
	sterilizers for humans (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	<u>goods and services subject to state monopoly in commercial activities).</u>	
4	4772: Retailing medicines, medical equipment, cosmetics, and cleaning materials Details: Retailing medical instruments, cosmetics and hygiene products in specialized stores (excluding retail of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	4772: Retail sale of medicines, medical instruments, cosmetics and personal hygiene products Details: Retail sale of medical instruments, cosmetics and personal hygiene products in specialized stores (excluding goods on the list of goods that foreign investors and foreign-invested economic organizations are not permitted to exercise export rights, import rights, or distribution rights, <u>and goods on the list of goods and services subject to State monopoly in the commercial sector).</u>	- To revise the wording and add: "(...and goods on the list of goods and services subject to State monopoly in the commercial sector)".



In the event that, at the request of a competent state authority, the wording of the newly added business lines must be amended without changing the substance of such newly added business lines, the Board of Directors shall be authorized to make the necessary adjustments in accordance with the request of the competent state authority.

2. Amendment and supplement to the Company's Charter

Based on the amendment and addition of the business lines mentioned above, the Board of Directors respectfully submits to the AGM for approval the amendment and





supplementation of Clause 1 Article 4 (Business lines of the Company) of the Charter to reflect the aforesaid changes.


Respectfully submitted to the AGM for consideration and approval.

**ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRMAN**



SUNG MIN WOO

)



IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 09 /TTr-HĐQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re: Amendments and supplements to the Charter of Imexpharm Corporation

To: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly on 17 June 2020, as amended by Law No. 03/2022/QH15 dated 11 January 2022;
- Pursuant to the Law on Pharmacy No. 105/2016/QH13 dated 06 April 2016 of the National Assembly, as amended and supplemented by Law No. 28/2018/QH14 dated 15 June 2018 and Law No. 44/2024/QH15 dated 21 November 2024, which takes effect from 01 July 2025;
- Pursuant to the Prime Minister's Decision No. 36/2025/QĐ-TTg dated 29 September 2025 on the promulgation of the Vietnam Standard Industrial Classification;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated 26 November 2019 and its subsequent amending and supplementing instruments;
- Pursuant to the Government's Decree No. 155/2020/ND-CP dated 31 December 2020 detailing the implementation of a number of articles of the Law on Securities;
- Pursuant to the Government's Decree No. 245/2025/ND-CP dated 11 September 2025 amending and supplementing a number of articles of Decree No. 155/2020/ND-CP;
- Pursuant to the Charter on Organization and Operation of Imexpharm Corporation (the "Company")

The Board of Directors (the "BOD") respectfully submits to the 2025 Annual General Meeting of Shareholders (the "AGM") for consideration and approval the amendments and supplements to certain articles of the Charter of Imexpharm Corporation as follows:

1. Amendments and supplements to Clause 1, Article 4 – Business lines of the Company

No.	Current business line content	Proposed amendments and supplements	Remarks
1	<p>4649: Trading household appliances</p> <p>Details: Wholesaling cosmetics (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).</p>	<p>4649: Wholesale of other household goods</p> <p>Details:</p> <ul style="list-style-type: none"> - Export of drugs and drug materials. - Import of drugs and drug materials. - Wholesale of drugs and drug materials manufactured by the Company, contract-manufactured or transferred by technology in Vietnam to medical examination and treatment establishments, vaccination establishments and other medical establishments; drug rehabilitation establishments; state drug and drug-material testing establishments; science and technology organizations and training establishments conducting research and teaching related to pharmacy; pharmaceutical business establishments; and establishments that have been granted an Investment Registration Certificate for drug manufacturing but have not yet been granted a Certificate of eligibility for pharmaceutical business for pilot production and assessment of drug manufacturing processes. 	<p>Addition of business lines: Wholesale, import and export of medicines, pharmaceutical raw materials, pursuant to Article 53a of Law No. 44/2024/QH15 dated November 21, 2024 amending and supplementing certain articles of the Law on Pharmacy.</p>





No.	Current business line content	Proposed amendments and supplements	Remarks
		<ul style="list-style-type: none"> - Wholesale of drugs and drug materials imported by the Company to drug and drug-material wholesalers. - Wholesale, import and export of cosmetics. 	
2	<p>4632: Wholesaling food</p> <p>Details: Wholesaling food, functional foods, drinks, alcoholic and carbonated drinks (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).</p>	<p>4632: Wholesale of food</p> <p>Details: Wholesale and <u>import/export</u> of food, functional foods, beverages, alcoholic beverages and carbonated drinks (excluding the wholesale and <u>import/export</u> of goods on the list of goods for which foreign investors and foreign-invested economic organizations are not allowed to exercise the right to export, the right to import and the right to distribute).</p>	To supplement the function of import and export of food
3	<p>4669: Other uncategorized specialized wholesale</p> <p>Details: Wholesaling, importing/exporting medical equipment (excluding video recording products and goods under the list of goods and services on which state monopoly is applied) and medical instruments, chemicals and raw materials, chemicals for the production of functional foods, disinfectants and sterilizers for humans (excluding wholesale of goods under</p>	<p>4679: Other specialized wholesale not elsewhere classified</p> <p>Details: Wholesale and import/export of medical equipment and instruments, chemicals and raw materials and chemicals for the manufacture of functional foods, and disinfectants and antiseptics for humans (excluding the wholesale of goods on the list of goods for which foreign investors and foreign-invested economic organizations are not allowed to exercise the right to export, the right to import and the right to distribute, <u>and</u></p>	<ul style="list-style-type: none"> - To change the level-4 business line code from 4669 to 4679, and update it in accordance with Appendices 1 and 2 to Decision No. 36/2025/QD-TTg of the Prime Minister dated 29 September 2025 on the promulgation of the Vietnam

0384
IG T
C P
XPH
ÔNG



No.	Current business line content	Proposed amendments and supplements	Remarks
	the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	<u>goods and services on the list of goods and services subject to state monopoly in commercial activities).</u>	Standard Industrial Classification. - To revise the wording and add: "(... and goods and services on the list of goods and services subject to state monopoly in commercial activities)"
4	<p>4772: Retailing medicines, medical equipment, cosmetics, and cleaning materials <u>in specialized stores</u></p> <p>Details: Retailing medical instruments, cosmetics and hygiene products in specialized stores (excluding retail of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).</p>	<p>4772: Retail sale of medicines, medical instruments, cosmetics and personal hygiene products</p> <p>Details: Retail sale of medical instruments, cosmetics and personal hygiene products in specialized stores (excluding goods on the list of goods that foreign investors and foreign-invested economic organizations are not permitted to exercise export rights, import rights, or distribution rights, <u>and goods on the list of goods and services subject to State monopoly in the commercial sector).</u></p>	<p>- To change the names of level-4 business lines by removing the phrase "in specialized stores" and updating them in accordance with Appendices 1 and 2 of Decision No. 36/2025/QĐ-TTg dated 29 September 2025.</p> <p>- To revise the wording and add: "(...and goods on the list of goods and services subject to State monopoly in the commercial sector)".</p>

1433-C
Y CP
HÀM
ARM
THÁP



2. Supplement to Article 26. Composition and Term of Members of the Board of Directors

No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
1	Eligibility of members of the Board of Directors	Article 26	No existing provision	<p>Article 26. Composition, Term, and Eligibility of Members of the Board of Directors</p> <p>Addition of Clause 7 to Article 26</p> <p>7. A member of the Board of Directors of the Company may concurrently serve as a member of the Board of Directors or Members' Council of a maximum of 05 (five) other companies.</p>	Article 275 of Decree No. 155/2020/ND-CP as amended by Clause 78, Article 1 of Decree No. 245/2025/ND-CP dated September 11, 2025

3. Amendments and Supplements to Article 27. Rights and obligations of the Board of Directors

No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
1	Rights and obligations of the Board of Directors	Article 27	<p>Article 27. Rights and obligations of the Board of Directors</p> <p>1. The business operations and affairs of the Company shall be subject to the supervision and direction of the Board of Directors. The Board of Directors is a body with full power to exercise all the rights and obligations on behalf of the Company, except the powers</p>	<p>Article 27. Powers, duties and responsibilities of the Board of Directors</p> <p>1. The Board of Directors is the managerial body of the Company and has full authority, on behalf of the Company, to decide on and exercise the rights and obligations of the Company, except for those rights and obligations that fall under the authority of the General Meeting of Shareholders.</p> <p>2. The Board of Directors has the following rights and duties:</p>	<p>Article 153 of the Law on Enterprises</p> <p>Articles 277 and 278 of Decree No. 155/2020/ND-CP, as amended and</p>

No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>of the General Meeting of Shareholders.</p> <p>2. The rights and obligations of the BOD are prescribed by law, the Corporation's Charter and the AGM. Specifically, the BOD has the following rights and obligations:</p> <p>a. To make decisions on medium term development strategies, and plans, and on annual business plans of the Company;</p> <p>b. To define the operational objectives on the basis of the strategic objectives approved by the General Meeting of Shareholders;</p> <p>c. To appoint and dismiss, sign and terminate contracts for the General Director, Deputy General Directors, Chief Accountant at the request of the General Director and decide on their remuneration;</p> <p>d. Supervise and direct the General Director and other Executives;</p>	<p>a) To decide on the Company's strategy, medium-term development plan and annual business plan;</p> <p>b) To propose classes of shares and the total number of shares of each class to be offered;</p> <p>c) To decide the sale of unsold shares within the total number of shares of each class permitted to be offered; to decide on additional capital mobilization in other forms;</p> <p>d) To decide the selling prices of the Company's shares and bonds;</p> <p>e) To decide the repurchase of shares in accordance with Clause 1 and Clause 2 Article 133 of the Law on Enterprises;</p> <p>f) To decide investment plans and investment projects within its authority and limits in accordance with law;</p> <p>g) To decide solutions for market development, marketing and technology;</p> <p>h) To approve purchase, sale, borrowing, lending contracts and other contracts and transactions with a value of 35% or more of the total asset value recorded in the latest financial statements of the Company, except for contracts and transactions falling under the authority of the General Meeting of</p>	<p>supplemented by Clauses 80 and 81 Article 1 of Decree No. 245/2025/ND-CP dated 11 September 2025</p>



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>e. Resolve the complaint of the Company about executive team as well as the decision to designate the Company's representatives to resolve issues related to the legal procedures concerning such executives;</p> <p>f. Decide the organizational structure, establishment of subsidiaries, branches, representative office, capital contributions to or purchase of shares of other enterprises;</p> <p>g. Propose the re-organization or dissolution of the company;</p> <p>h. Decide on internal regulations of corporate governance after being approved by the General Meeting of Shareholders to protect shareholders;</p> <p>i. Approve the agenda, materials used in sessions of the Shareholders' Meeting, convene sessions of the Shareholders' Meeting or collect written opinions for the adoption of</p>	<p>Shareholders as prescribed in Point d Clause 2 Article 138, Clause 1 and Clause 3 Article 167 of the Law on Enterprises;</p> <p>i) To elect, dismiss and remove the Chairperson of the Board of Directors; to appoint, dismiss, enter into and terminate contracts with the General Director, Deputy General Directors, Chief Accountant, Chief Financial Officer, Corporate Governance Officer; to decide salaries, remuneration, bonuses and other benefits of such managers; to appoint authorized representatives to participate in the Members' Council or General Meeting of Shareholders of other companies and decide on their remuneration and other benefits;</p> <p>j) To supervise and direct the General Director and other managers in managing the Company's day-to-day business operations;</p> <p>k) To decide on the organizational structure and internal management regulations of the Company; to decide on the establishment of subsidiaries, branches and representative offices and the capital contribution to, and purchase of shares in, other enterprises;</p> <p>l) To approve the agenda, contents and documents serving meetings of the General Meeting of Shareholders, to convene meetings of the General</p>	



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>decisions of the Shareholders' Meeting;</p> <p>j. Propose the annual dividend payment rate; decide on the timeline and procedures for paying dividends;</p> <p>k. Propose classes of shares to be issued and the total number of issued shares for each class;</p> <p>l. Propose the issuance of convertible bonds and warrant-linked bonds;</p> <p>m. Decide the offering price of bonds, stocks in the case of authorization from the General Meeting of Shareholders;</p> <p>n. Submit annual audited financial statements and the report of the Supervisory Board to the AGM;</p> <p>o. Make report to the General Meeting of Shareholders on the appointment of the General Director of the Board of Directors;</p> <p>3. The following matters shall be approved by the Board of Directors:</p>	<p>Meeting of Shareholders or solicit written opinions of shareholders to pass resolutions;</p> <p>m) To submit annual financial statements to the General Meeting of Shareholders;</p> <p>n) To propose the dividend rate; to decide the time limit and procedures for dividend payment or handling of losses arising in the course of business operations;</p> <p>o) To propose the reorganization or dissolution of the Company; to request initiation of bankruptcy of the Company;</p> <p>p) Other rights and obligations in accordance with the Law on Enterprises and the Law on Securities.</p> <p>3. The Board of Directors shall ratify resolutions and decisions by voting at meetings, collecting written opinions or other online forms. Each member of the Board of Directors shall have one vote.</p> <p>4. Where a resolution or decision of the Board of Directors is passed in contravention of law, resolutions of the General Meeting of Shareholders or this Charter and causes damage to the Company, the members who voted in favor of such resolution or decision shall be jointly and severally personally liable for such resolution or decision and must compensate the Company for any damage; members who voted</p>	



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>a. Establishment of branches, representative offices of the Company;</p> <p>b. To establish the Company's subsidiaries;</p> <p>c. To the extend specified in Clause 2, Article 153 of the Law on Enterprises and except for the cases specified in Clause 2, Article 138 and Clause 1 and Clause 3, Article 167 of the Law on Enterprises which fall under the GMS's mandate, the Board of Directors shall decide to execute, revise and cancel the Company's contracts;</p> <p>d. Appoint and dismiss the persons authorized by the Company as commercial representative and Attorney at Law of the Company;</p> <p>e. The borrowing of loan and the implementation of the mortgages, securities, guarantees and compensations of the Company;</p>	<p>against such resolution or decision shall be exempt from liability. In this case, the shareholders of the Company have the right to request a court to suspend the implementation of or annul such resolution or decision.</p> <p>5. Responsibilities of the Board of Directors:</p> <p>a) To be responsible to the shareholders for the Company's operations.</p> <p>b) To treat all shareholders equally and respect the interests of persons having related interests to the Company.</p> <p>c) To ensure that the Company's operations comply with law, this Charter and the Company's internal regulations.</p> <p>d) To formulate the Regulation on the operation of the Board of Directors for submission to the General Meeting of Shareholders for approval and disclosure on the Company's website.</p> <p>e) To supervise and prevent conflicts of interest of members of the Board of Directors, members of the Audit Committee, the General Director and other managers appointed by the Board of Directors,</p>	



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>f. Approve contracts for purchase, sale, borrowing, lending, and other contracts and transactions valued at 35% or more of the total assets value recorded in the Company's latest financial statement;</p> <p>g. Purchase or sale of shares, contributed capital in other companies established in Vietnam or abroad;</p> <p>h. Decision on pricing of the non-cash assets contributed in the Company in the issuance of shares or bonds by the Company shall include gold, land use right, right on intellectual property, technology and technological know-how;</p> <p>i. Redemption or withdrawal of no more than 10% of the total number of of each type shares offered within 12 (twelve) months;</p>	<p>including misuse of Company assets and abuse of related-party transactions.</p> <p>f) To formulate internal regulations on corporate governance and submit them to the General Meeting of Shareholders for approval in accordance with Article 270 of Decree No. 155/2020/ND-CP detailing a number of articles of the Law on Securities.</p> <p>g) To appoint a Person in charge of Corporate Governance.</p> <p>h) To organize training and capacity-building in corporate governance and necessary skills for members of the Board of Directors, the General Director, the Corporate Governance Officer and other managers of the Company.</p> <p>i) To report on the activities of the Board of Directors at the General Meeting of Shareholders in accordance with Article 280 of Decree No. 155/2020/ND-CP detailing the implementation of the Law on Securities.</p> <p>j) The Company shall pay dividends to shareholders in accordance with law after the annual General Meeting of Shareholders has approved such dividend.</p> <p>6. Rights and obligations of members of the Board of Directors:</p>	

1.00
 ÔNG
 UỶ
 MEX
 H ĐỒ



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>j. Decision of the price for the purchase or redemption of the Company' shares;</p> <p>k. The business issues or transactions that according to the decision of the Board of Directors need to be approved by the Board within its scope of power and responsibility.</p> <p>4. The Board of Directors must report to the General Meeting of Shareholders about its operations, specifically the supervision of the Board of Directors over the General Director and other managers during the fiscal year. Where the Board fails to submit a report to the General Meeting of Shareholders, the Company's annual financial statements are considered invalid and not yet approved by the Board.</p> <p>5. Unless otherwise stated by the law and the Charter, the Board of Directors may authorize the staffs</p>	<p>6.1. Members of the Board of Directors shall have all rights as prescribed by the Law on Securities, relevant laws and the Charter of the Company, including the right to be provided with information and documents on the financial situation and business operations of the Company and its affiliated entities.</p> <p>6.2. Members of the Board of Directors shall have the following obligations:</p> <p>a) To perform their duties in an honest and prudent manner for the best interests of the shareholders and the Company.</p> <p>b) To fully attend meetings of the Board of Directors and give opinions on the matters submitted for discussion.</p> <p>c) To promptly and fully report to the Board of Directors on the remuneration received from subsidiaries, associates and other organizations.</p> <p>d) To report to the Board of Directors at the nearest meeting on transactions between the Company, its subsidiaries, and companies in which the Company holds 50% or more of the charter capital and such member of the Board of Directors and his/her related persons; and on transactions between the Company and any company in which such member of the Board</p>	

384
 G TY
 : PH
 PHA
 ONG



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			and managers to handle the works on behalf of the Company.	<p>of Directors is a founding shareholder or a manager within a period of 03 years immediately preceding the time of the transaction.</p> <p>e) To disclose information upon conducting transactions in the Company's shares in accordance with law.</p> <p>6.3. Each independent member of the Board of Directors of the Company must prepare a report on the assessment of the performance of the Board of Directors.</p>	

4. To abolish Clause 5 Article 37. Responsibilities for honesty and avoidance of conflicts of interest.

To add Article 37a. Approval of contracts and transactions between the Company and related persons as follows:


No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
1	Giao dịch với bên có liên quan	Khoản 5 Điều 37. Trách nhiệm trung thực và tránh các xung đột	Clause 5, Article 37 Contracts or transactions between the Company and one or more of the BOD members, General Director and other managers and their related organizations/persons or a company, partner, association, or organization where the BOD members, the General Director	<p>Article 37a. Approval of contracts and transactions between the Company and related persons</p> <p>1. The General Meeting of Shareholders or the Board of Directors shall approve the following contracts and transactions between the Company and its related persons:</p> <p>a. Shareholders, authorized representatives of institutional shareholders owning more than 10% of the total number</p>	<p>To abolish Clause 5 Article 37 and add Article 37a.</p> <p>To update in accordance with Article</p>

No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
		về quyền lợi	<p>other managers or their related persons serve as a member, or have related financial interest shall not be nullified in the following cases:</p> <p>a. For contracts with a value smaller than or equal to 20% (twenty percent) of the total value of assets recorded in the most recent financial statements, the key elements of the contracts or transactions as well as the relationships and interests of the members of the Board of Directors, General Director and other managers are reported to the Board of Directors. In addition, the Board of Directors which has approved the execution of such contract or transaction honestly by a majority of votes from the members of the Board does not have any related interests;</p>	<p>of the Company's ordinary shares, and their related persons;</p> <p>b. Members of the Board of Directors, the General Director, and their related persons;</p> <p>c. Enterprises which members of the Board of Directors, members of the Audit Committee, the General Director, Deputy General Directors, the Chief Accountant and other managers appointed by the Board of Directors of the Company must declare in accordance with Clause 2 Article 164 of the Law on Enterprises.</p> <p>2. The Board of Directors shall approve the contracts and transactions prescribed in Clause 1 of this Article which have a value of less than 35% of the total asset value of the Company as recorded in the latest financial statements. In this case, the person representing the Company to sign the contracts or transactions must notify the members of the Board of Directors and the Audit Committee of the related persons to such contracts or transactions and attach the draft contract or the principal contents of the transaction. The Board of Directors shall decide on the approval of the contracts or transactions within 15 days from the date of receipt of the notice, and members of the Board of Directors</p>	<p>167 of the Law on Enterprises. Approval of contracts and transactions between the company and related persons.</p>



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>b. For contracts with a value greater than 20% (twenty percent) of the total value of assets recorded in the most recent financial statements, the key elements of the contracts or transactions as well as the relationships and interests of the members of the Board of Directors, General Director and other managers are disclosed to the shareholders having no related interests and having the right to vote on that issue, and those shareholders have voted to approve such contracts or transactions;</p> <p>c. The contracts or transactions are regarded as fair and reasonable by an independent consulting firm in all aspects related to the company's shareholders at the time the transactions or contracts are approved by the Board of Directors or the General Meeting</p>	<p>having related interests in the parties to the contracts or transactions shall not have the right to vote.</p> <p>3. The General Meeting of Shareholders shall approve the following contracts and transactions:</p> <p>a. Contracts and transactions other than those stipulated in Clause 2 of this Article;</p> <p>b. Loan, borrowing and asset sale contracts and transactions with a value greater than 10% of the total asset value of the enterprise as recorded in the latest financial statements, entered into between the Company and a shareholder owning 51% or more of the total voting shares or a related person of such shareholder.</p> <p>4. In the case of approving contracts and transactions as prescribed in Clause 3 of this Article, the person representing the Company to sign the contracts or transactions must notify the Board of Directors and the Audit Committee of the related persons to such contracts or transactions and attach the draft contract or a notice of the principal contents of the transaction. The Board of Directors shall submit the draft contracts or transactions or provide explanations on the principal contents of the contracts or transactions at the General Meeting of Shareholders or seek written opinions from shareholders. In this case, shareholders having related</p>	

0384
 NG TY
 C PH
 XPH
 ĐÔNG



No.	Content	Article/ Clause	Old Charter Content	New Charter Content	Notes
			<p>of Shareholders. Members of the Board of Directors, General Director, other managers and related organizations/persons of the aforesaid members must not use the information not yet publicly disclosed by the Company or disclose such information to others to carry out related transactions.</p>	<p>interests in the parties to the contracts or transactions shall not have the right to vote; the contracts or transactions shall be approved in accordance with Clause 1 and Clause 4 Article 148 of the Law on Enterprises.</p> <p>5. Contracts and transactions shall be invalidated under a court decision and handled in accordance with law if they are entered into in contravention of the provisions of this Article; the person signing the contracts or transactions, the shareholders, members of the Board of Directors or the General Director concerned shall be jointly liable to compensate for any arising damage and return to the Company any benefits obtained from the performance of such contracts or transactions.</p> <p>6. The Company must disclose related-party contracts and transactions in accordance with the relevant laws.</p>	

433-C
CP
HÀM
RM
THÁP



Respectfully submitted to the Annual General Meeting of Shareholders for consideration and approval.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN



SUNG MIN WOO







VOTING SLIP AT THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Full name of shareholder:


ID card/Passport/Business Registration Certificate No.:

Shareholder code:

Number of shares owned: shares

Matters for voting:

No.	Matters for voting	Voting opinions		
		Agree	Disagree	No opinion
1	2025 Financial Statements audited by Branch of KPMG Limited (Vietnam)			
2	Report and assessment of the Board of Directors' activities in 2025, strategic orientations and targets for the 2026 plan			
3	Report on business and financial performance of the Executive Board in 2025, 2026 business plan and key solutions			
4	Report of the Audit Committee and independent BOD member – Mr. Hoang Duc Hung			
5	Report of the independent BOD member – Mr. Chung Suyong			
6	Proposal on profit distribution, dividend payment for 2025 and dividend plan for 2026			
7	Proposal on 2026 business targets and plan			
8	Proposal on 2026 operating expenses, remuneration and bonuses of the Board of Directors and BOD Committees			
9	Proposal on selection of the independent auditing firm, and authorization for the Board of Directors to select one (01) out of four (04) audit firms, based on the selection criteria, to review the interim financial statements 2026 and audit the 2026 financial statements			
10	Proposal on amendments and supplements to the Company's business lines			



No.	Matters for voting	Voting opinions		
		Agree	Disagree	No opinion
11	Proposal on amendments and supplements to the Company's Charter			

....., date month 2026

Shareholder/Authorized representative of shareholder

((Sign, full name and seal (if any))



IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIET NAM

Independence - Freedom - Happiness

No.: /NQ-ĐHĐCĐ-IMP

Ho Chi Minh City, April 22, 2026

Draft



RESOLUTION

**THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
IMEXPHARM CORPORATION**

THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 dated 17 June 2020 and its subsequent amending and supplementing laws;*
- *The Law on Securities No. 54/2019/QH14 dated 26 November 2019 and its subsequent amending and supplementing laws;*
- *The Government's Decree No. 155/2020/ND-CP dated 31 December 2020 detailing the implementation of a number of articles of the Law on Securities;*
- *The Government's Decree No. 245/2025/ND-CP dated 11 September 2025 amending and supplementing a number of articles of Decree No. 155/2020/ND-CP;*
- *The Charter on Organization and Operation of Imexpharm Corporation;*
- *The Minutes of the 2026 Annual General Meeting of Shareholders of Imexpharm Corporation No./BB-ĐHĐCĐ-IMP dated 22 April 2026.*

RESOLVES

Article 1.

The 2026 Annual General Meeting of Shareholders (the AGM) approves the 2025 financial statements audited by the Ho Chi Minh City Branch of KPMG Company Limited (Vietnam).

Article 2.

The AGM approves the 2025 report on activities and business performance assessment of the Board of Directors, and the strategic orientations and target plans for 2026 as presented at the Meeting.

Article 3.

The AGM approves the 2025 report on business and financial performance of the Executive Board and the key operational plan for 2026 as presented at the Meeting.



Article 4.

The AGM approves the report of the Audit Committee and the report of the independent member of the Board of Directors - Mr. Hoang Duc Hung.

Article 5.

The AGM approves the report of the independent member of the Board of Directors - Mr. Chung Suyong.

Article 6.

The AGM approves the proposal on profit distribution, dividend payment for 2025 and dividend plan for 2026.

1. Profit distribution for 2025

No.	Description	Proportion	Amount (VND)
1	Total profit before tax for 2025		446,247,738,093
2	Total profit after tax for 2025		349,138,023,396
3	(-) Utilization of Development Investment Fund		4,803,003,971
4	(-) Gain from foreign exchange revaluation		(1,884,766)
5	(+) Retained earnings from previous years		95,072,379,977
6	Profit available for distribution	100.00%	449,011,522,578
	Cash dividend payment of 6% of charter capital		
7	(154,008,962 shares × 600 VND/share)	20.58%	92,405,377,200
8	Bonus and welfare fund	10.91%	49,000,000,000
9	Undistributed retained earnings	68.51%	307,606,145,378

2. Dividend for 2025: 6% of Charter Capital in Cash

The Company pays dividends to shareholders within 30 days after receiving the shareholder list from the Vietnam Securities Depository and Clearing Corporation (VSDC), but no later than 3 months from the conclusion of the 2026 AGM.

3. Dividend plan for 2026

The cash dividend rate for 2026 is expected to be 5%–8% of charter capital, and the Board of Directors shall be authorized to decide the specific rate depending on the Company's 2026 business results.



Article 7.

The AGM approves the proposal on the 2026 business targets and plan as follows:

No.	Target	Unit	Actual for 2025	Plan 2026	Growth
1	Total Revenue	VND Billion	2.914,3	3.200,0	9,8%
2	Profit before tax	VND Billion	446,2	502,0	12,5%
3	EBITDA	VND Billion	567,2	637,0	12,3%

Article 8.

The AGM approves the proposal on the 2026 remuneration and operating expenses plan of the Board of Directors (the BOD) and BOD's Committees as follows:

1. Remuneration and expenses for the BOD and Board Committees

- The appropriation rate is 2% of Profit Before Tax (PBT), calculated before the deduction of actual expenses incurred for the BOD and the Board Committees.

2. Bonuses for the achievement of profit targets

- Profit-plan completion bonus: The Board of Directors and its Committees shall be awarded a bonus equal to 1% of profit after tax if the Company fulfills its 2026 profit-before-tax plan.
- Bonus on profit exceeding the plan: The BOD and BOD Committees are entitled to a bonus equal to 5% of the portion of profit before tax that exceeds the target.

Article 9.

The AGM approves the proposal on the selection of the independent audit firm and authorizes the Board of Directors of the Company to select one (01) of the following four (04) audit firms, based on the approved selection criteria, to review the 2026 semi-annual financial statements and audit the 2026 annual financial statements.

The list of the four audit firms includes:

1. KPMG Vietnam Company Limited
2. Grant Thornton (Vietnam) Limited
3. Deloitte Vietnam Company Limited
4. Ernst & Young Vietnam Limited.

Article 10.


The AGM approves the proposal on amendment and supplementation of the business lines



of Imexpharm Corporation, with details as follows:

No.	Current business line description	Proposed amendments and supplementations	Remarks
1	<p>4649: Trading household appliances</p> <p>Details: Wholesaling cosmetics (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).</p>	<p>4649: Wholesale of other household goods</p> <p>Details:</p> <ul style="list-style-type: none"> - Export of drugs and drug materials. - Import of drugs and drug materials. - Wholesale of drugs and drug materials manufactured by the Company, contract-manufactured or transferred by technology in Vietnam to medical examination and treatment establishments, vaccination establishments and other medical establishments; drug rehabilitation establishments; state drug and drug-material testing establishments; science and technology organizations and training establishments conducting research and teaching related to pharmacy; pharmaceutical business establishments; and establishments that have been granted an Investment Registration Certificate for drug manufacturing but have not yet been granted a Certificate of eligibility for pharmaceutical business for pilot production and 	<p>Addition of business lines: Wholesale, import and export of medicines, pharmaceutical raw materials, pursuant to Article 53a of Law No. 44/2024/QH15 dated November 21, 2024 amending and supplementing certain articles of the Law on Pharmacy.</p>

384
 3 T
 3 P
 PH
 ONG



No.	Current business line description	Proposed amendments and supplementations	Remarks
		assessment of drug manufacturing processes. - Wholesale of drugs and drug materials imported by the Company to drug and drug-material wholesalers. - Wholesale, import and export of cosmetics.	
2	4632: Wholesaling food Details: Wholesaling food, functional foods, drinks, alcoholic and carbonated drinks (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	4632: Wholesale of food Details: Wholesale and <u>import/export</u> of food, functional foods, beverages, alcoholic beverages and carbonated drinks (excluding the wholesale and <u>import/export</u> of goods on the list of goods for which foreign investors and foreign-invested economic organizations are not allowed to exercise the right to export, the right to import and the right to distribute).	To supplement the function of import and export of food
3	4679: Other uncategorized specialized wholesale Details: Wholesaling, importing/exporting medical equipment (excluding video recording products and goods under the list of goods and services on which state monopoly is applied) and medical	4679: Other specialized wholesale not elsewhere classified Details: Wholesale and import/export of medical equipment and instruments, chemicals and raw materials and chemicals for the manufacture of functional foods, and disinfectants and antiseptics for humans (excluding the wholesale of goods on the list of goods for which foreign investors and	- To revise the wording and add: "(... and goods and services on the list of goods and services subject to state monopoly in commercial activities)"

 433
 'C
 IAN
 AR
 TH


No.	Current business line description	Proposed amendments and supplementations	Remarks
	instruments, chemicals and raw materials, chemicals for the production of functional foods, disinfectants and sterilizers for humans (excluding wholesale of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	foreign-invested economic organizations are not allowed to exercise the right to export, the right to import and the right to distribute, <u>and goods and services on the list of goods and services subject to state monopoly in commercial activities</u>).	
4	4772: Retailing medicines, medical equipment, cosmetics, and cleaning materials Details: Retailing medical instruments, cosmetics and hygiene products in specialized stores (excluding retail of goods under the list of goods prohibited for export, import and distribution by foreign investors, foreign-invested business entities).	4772: Retail sale of medicines, medical instruments, cosmetics and personal hygiene products Details: Retail sale of medical instruments, cosmetics and personal hygiene products in specialized stores (excluding goods on the list of goods that foreign investors and foreign-invested economic organizations are not permitted to exercise export rights, import rights, or distribution rights, <u>and goods on the list of goods and services subject to State monopoly in the commercial sector</u>).	- To revise the wording and add: "(...and goods on the list of goods and services subject to State monopoly in the commercial sector)".

In the event that, at the request of a competent state authority, the wording of the newly added business lines must be amended without changing the substance of such newly added business lines, the Board of Directors shall be authorized to make the necessary adjustments in accordance with the request of the competent state authority.

To concurrently approve the amendment and supplementation of Clause 1 Article 4 of the



Company's Charter on the Company's business lines, corresponding to the aforesaid amendments and additions to the business lines.

Article 11.

The AGM approves the proposal on amendment and supplementation of the Charter of Imexpharm Corporation.

Article 12.

This Resolution takes effect from the closing date of the 2026 AGM.

The AGM authorizes the Board of Directors to direct the organization and implementation of the contents of this Resolution.

All shareholders of Imexpharm Corporation, members of the Board of Directors, the Executive Board and all employees of the Company shall be responsible for implementing this Resolution.

Recipients:

- Shareholders of the Company
- BOD
- BOM
- Disclosure
- Filing: Admin, AGM Secretary.

**FOR AND ON BEHALF OF
THE PRESIDUM
CHAIRPERSON**

